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With unloading, muscle atrophy and weakness occur due to changes in both 
protein synthesis and degradation.  The long term goal is to increase understanding of 
mechanisms underlying the losses in mass and force generation associated with muscle 
disuse.  Our approach was to target both protein degradation, through inhibition of the 
protease calpain, and growth pathways, through inhibition of deacetylase activity, during 
hindlimb suspension (HS) to assess the effectiveness for ameliorating structural and 
functional declines in muscle with unloading.  Calpain was inhibited by muscle-specific 
over-expression of calpastatin in transgenic (cp) mice, and in separate experiments, 
deacetylase activity was inhibited by treatment with trichostatin A (TSA), previously 
shown to promote myoblast fusion in culture and induce hypertrophy in dystrophic 
muscle in vivo.  Compared with non-suspended control mice, after 14 days of HS, soleus 
muscles of wild type (wt) mice showed declines of 25-40% in mass, maximum isometric 
force (Po), and specific Po normalized for total muscle fiber cross-sectional area (CSA), 
while muscles of cp mice exhibited similar declines in mass but no change in specific Po.  
Consistent with preservation of specific Po during HS, muscles of cp mice also 
maintained sarcomere structure, in contrast to wt muscles that demonstrated 
misalignment of Z-lines and decreased uniformity of thick filament lengths.  We conclude 
that inhibition of calpain proteolytic activity during unloading preserves sarcomere 
structure and isometric force generating capacity but does not protect from muscle 
x 
 
atrophy.  In contrast, treatment with TSA did little to ameliorate the loss of muscle mass 
during HS and provided no protection from the decrease in specific Po induced by 
unloading.  Although treatment with TSA was ineffective for protecting muscles from 
atrophy or weakness, individual fiber CSAs were 30-40% larger in TSA treated than in 
vehicle treated mice after 21 days of HS.  These findings indicate that inhibition of 
deacetylase activity is capable of inducing fiber growth, even in atrophying muscle.  In 
conclusion, calpain inhibition may be an effective target for preventing muscle weakness 
during disuse, by minimizing proteolytic damage to the force generating apparatus, 
especially in combination with therapies targeting growth pathways for preventing 











The fully differentiated skeletal muscle cell is uniquely suited to generate force 
and, through its attachment through tendons or tendon-like structures to the skeleton, to 
produce movement.  A structural hierarchy divides the whole muscle tissue into 
individual parallel running fibers, in which eighty percent of the volume is occupied by 
parallel running approximately cylindrical myofibrils.  The myofibrils are in turn composed 
of a highly ordered array of interdigitating protein filaments.  Cyclical interactions 
between the myosin molecules of the thick filaments and the actin molecules of the thin 
filaments result in the sliding of thick and thin filaments past one another and the 
generation of movement.  Under circumstances when filament sliding is resisted, the 
cyclical interactions result in force generation.  During development, individual skeletal 
muscle fibers differentiate into various types with widely varying contractile properties, 
providing the ability for the muscular system to match its structure and function to the 
habitual level of activity.  Moreover, alterations in activity patterns, such as changes in 
loading, can induce adaptations in the expression and organization of muscle specific 
proteins to once again match the new pattern of activity (Lieber 2002).  Fiber types vary 
with respect the myosin isoforms expressed, type 1 slow or type 2 fast, and the capacity 




Skeletal Muscle Unloading by Hindlimb Suspension Induces Muscle Atrophy and 
Weakness 
Deficits in skeletal muscle structure and function are prominent features of 
several diseases including HIV/AIDS (Gonzalez-Cadavid et al. 1998), cancer (Spencer & 
Mellgren 2002; Russell et al. 2009), muscular dystrophy (Spencer & Mellgren 2002), 
sepsis (Williams et al. 1999), and diabetes (Price & Mitch 1998).  In addition, unloading 
of skeletal muscle during space flight (Gardetto et al. 1989; Tischler et al. 1993; Tischler 
& Slentz 1995; Widrick et al. 1997; Widrick et al. 1999; Bodine et al. 2001) or during a 
period of bed rest (Gardetto et al. 1989; Tischler et al. 1993; Tischler & Slentz 1995; 
Widrick et al. 1997; Widrick et al. 1999; Bodine et al. 2001) or immobilization due to 
casting of a limb (Gardetto et al. 1989; Tischler et al. 1993; Tischler & Slentz 1995; 
Widrick et al. 1997; Widrick et al. 1999; Bodine et al. 2001) induces substantial muscle 
atrophy, weakness, and changes in protein expression.  A commonly used experimental 
method for unloading the skeletal muscles of the hind limbs of rodents is hindlimb 
suspension (HS), also sometimes referred to as hindlimb unweighting (HU).  Multiple 
modified versions of the original methodology described by Morey et al. (1979) have 
since resulted in over 1300 publications.  Most HS methods are similar, and involve 
placing some form of small harness on the rodent’s tail that is used to suspend the hind 
legs just slightly off of the floor of the cage.  The tail is then connected by a pulley to a 
rod so that the animals can move freely around the cage with easy access to food and 
water. 
In conjunction with NASA, investigators have performed parallel studies 
demonstrating the similarity of the responses of skeletal muscles from rodents exposed 
to HS to those of muscles of rodents during the actual weightlessness of space (Tischler 
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et al. 1993; Ikemoto et al. 2001).  One response consistently reported following both HS 
and true weightlessness was a similar pattern of muscle atrophy.  During HS, skeletal 
muscle mass declines rapidly by as much as 40% within 2 weeks for rats (Fitts et al. 
1986).  During HS of rats as well as during space flight, the soleus muscles, normally 
weight bearing postural muscles, show a large degree of muscle atrophy while the 
extensor digitorum longus (EDL) muscles, non-weight bearing muscles, are much less 
affected.  In addition to the muscle atrophy induced by HS, associated losses in force 
are also observed.  Following 14 days of HS, both soleus and adductor longus muscles 
display atrophy, and permeabilized fibers from both muscles generate lower forces than 
fibers from muscles of non-suspended animals.  Moreover, fibers from soleus muscles 
exhibit weakness, i.e. a decrease in maximum isometric force in excess of what could be 
explained by atrophy, resulting in a decreased specific force (kN/m2) (Riley et al. 2005).  
Despite the consistency of the findings that slow muscles are primarily affected with HS 
or space flight in rats, studies utilizing muscle biopsy material from astronauts have 
shown that type 1 and type 2 fibers are similarly affected (Fitts et al. 2000).   
The mechanism underlying the loss of muscle mass and force during unloading 
induced by HS has been attributed to an imbalance in protein turnover where protein 
degradation is increased and protein synthesis is diminished (Haddad et al. 2003a; 
Haddad et al. 2003b).  The rate of myofibrillar protein synthesis declines rapidly over the 
first several days following the initiation of HS (Thomason et al. 1989).  The rapid 
decrease in myofibril protein synthesis rate does not appear to be due to decreased 
transcription, based on the observation that myosin heavy chain mRNA concentration 
was not decreased after 7 days of HS, a time point when myofibrillar protein synthesis 
had decreased by 59%.  Subsequent to the rapid decline in protein synthesis, the rate of 
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protein degradation slowly increases, peaking around Day 15 for soleus muscles of 
young rats and returning to pre-suspension values after about 3 weeks (Thomason et al. 
1989).  Further investigations of single fibers from rat soleus muscles showed a 25% 
reduction in the density of thin filaments following 14 days of HS that accompanied the 
decreased specific force values (Riley et al. 2005) and parallel findings from muscle 
samples of astronauts in orbit for 17 days on the space shuttle indicated that, compared 
with preflight samples, there was a 26% decrease in number of thin filaments and a 23% 
increase in susceptibility to contraction induced injury (Riley et al. 2000).  Finally, six 
weeks of bed rest induced a 40% reduction in specific force with a parallel decline in 
myofibrilllar protein content per muscle fiber volume (Larsson et al. 1996).  Each of these 
findings is consistent with a tip in the balance toward increased protein degradation with 
insufficient protein synthesis to compensate.  
 Detailed analyses of specific proteins targeted for degradation during disuse 
atrophy have focused recently on the giant sarcomere protein titin.  Titin filaments bind 
on one end to the Z-disc and on the other to multiple points along the thick filaments and 
serves as template for sarcomere assembly.  Titin is well recognized as the main 
determinant within muscle fibers of passive tension (Horowits et al. 1986; Funatsu et al. 
1990; Prado et al. 2005) and as such acts to maintain the thick filaments of the A-band 
in the central portion of the sarcomere.  Recently, Udaka and colleagues concluded that 
muscle disuse, achieved through immobilization of a limb by casting, induced changes 
within sarcomeres that were due to the preferential loss of titin in comparison to the 
unchanged levels of other myofibrilar proteins (Udaka et al. 2008).  Among the findings 
of the Udaka study were the observations of decreased mean thick filament length, 
decreased uniformity of thick filament length, decreased maximum isometric specific 
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force, and decreased passive force in response to six weeks of limb immobilization.  
Other investigators have reported decreased passive tension of whole soleus muscles 
(Caiozzo et al. 2007) and permeabilized single soleus fibers (Toursel et al. 2002) 
following HS that was accompanied by decreased titin levels in the muscles (Toursel et 
al. 2002).   
Thus, while disuse clearly results in reductions in muscle protein levels as well as 
decreases in force generating capability, the molecular mechanisms for these changes 
are still incompletely understood.  Although skeletal muscle has an enormous capacity to 
remodel and adapt in response to alterations in usage, an increased understanding of 
the regulatory events that contribute to the loss of muscle mass and force would improve 
our ability to design interventions aimed at maintaining functional capacity under 
circumstances when muscles are exposed to decreased loads (Stein & Wade 2005).  
Thus, the long term goal of this thesis work is to increase understanding of the 
mechanisms underlying the losses in mass and force associated with unloading.  Our 
approach was to target both muscle protein degradation and growth pathways during HS 
to assess the effectiveness for ameliorating structural and functional declines.   
 
Protein Degradation Pathways in Skeletal Muscle 
 Skeletal muscle contains four primary proteolytic systems that that contribute to 
the turnover of muscle proteins: 1. the lysosomal system, 2. the caspase system, 3. the 
ubiquitin-proteasome system, and 4. the calpain system (Goll et al. 2008).  Several 
studies have investigated the relative contributions to disuse skeletal muscle atrophy of 
these various proteolytic systems (Taillandier et al. 1996; Spencer et al. 1997; Bodine et 
al. 2001).  One study performed on rats flown on the Space Shuttle STS-90 analyzed 
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three of the major proteolytic pathways, namely the calpain, lysosomal, and ubiquitin 
proteasome pathways, and reported increased cleavage of myosin heavy chain that was 
specifically correlated with increased expression of components of the ubiquitin-
proteasome system (Ikemoto et al. 2001).  Furthermore, daily injections of a calpain 
inhibitor did not prevent the muscle atrophy in the rats leading the authors to conclude 
that the atrophy was mediated specifically by the ubiquitin proteasome system (Ikemoto 
et al. 2001), although no data confirming entry of the inhibitor into the muscles let alone 
the inhibition of calpain activity was provided (Tidball & Spencer 2002).   
Additional support for the importance of the ubiquitin-proteasome system in 
muscle atrophy was provided by the highly significant work of Bodine and her colleagues 
in the early part of this decade (Bodine et al. 2001).  That study demonstrated that the 
expression of two muscle-specific ubiquitin ligases, namely the Muscle Atrophy F-box 
(MAFbx, also known as atrogin-1) and the Muscle RING Finger-1 (MuRF1), increased in 
response to multiple different interventions that induced muscle atrophy. Moreover, over-
expression of MAFbx in myotubes was reported to reduce myotube size, whereas mice 
deficient in either MAFbx or MuRF1 displayed an attenuation of muscle atrophy following 
denervation compared with wild type littermates (Bodine et al. 2001).  Despite this 
compelling evidence supporting a role of MAFbx and MuRF1 in myofibrillar protein 
degradation during muscle atrophy, the exact role, mode of regulation, and target 
substrates of MAFbx and MuRF1 remain unknown (Glickman & Ciechanover 2002).  Of 
particular importance, is the observation that the ubiquitin-proteasome system does not 
does not appear able to target and degrade intact myofibrils (Koohmaraie 1992; 
Solomon & Goldberg 1996; Williams et al. 1999; Jagoe & Goldberg 2001).  Thus, 
myofibrillar proteins may need to first be cleaved and/or released from the myofibrils by 
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other degradative pathways to provide substrate for ubiquitination.  The accumulation of 
the resultant protein fragments has been hypothesized to then generate a positive 
feedback signal resulting in increased proteasome activity (Li et al. 2004b).  
 The calpain system has been postulated to be the proteolytic system that is 
critical for cytoskeletal remodeling during the early phase of the muscle response to 
alterations in loading (Kandarian & Stevenson 2002; Goll et al. 2003; Fareed et al. 
2006).  Although numerous myofibrillar proteins are substrates for calpain, conflicting 
observations have been made about the action of calpains during skeletal muscle 
atrophy.  Some investigators have reported no increases in the mRNA or activity of 
calpains during HS or spaceflight (Spencer et al. 1997; Ikemoto et al. 2001; Stevenson 
et al. 2003), while others have reported significant increases during unloading by HS or 
spinal cord transaction (Taillandier et al. 1996; Haddad et al. 2003a).  Other studies 
showed that inhibition of calpains in vitro prevented accelerated proteolysis in muscles 
harvested after 3 days of HS (Tischler et al. 1990), whereas another study indicated that 
in vitro inhibition of calpains after 9 days of HS prevented only a small percentage of 
muscle proteolysis (Taillandier et al. 1996).  While the contradictory nature of these 
investigations is difficult to completely resolve, it is fair to say that the extent to which 
such in vitro assessments mimic the proteolytic process in an atrophying muscle in vivo 
is unclear.  Despite, the disparities among in vitro studies, support for the importance of 
calpain as a mediator of protein degradation in skeletal muscle during atrophy is 
provided by the observation that treatment of rats with calpain inhibitors prevented 
sepsis-induced muscle proteolysis with no change in the expression of the MAFbx and 
MURF-1 ubiquitin ligases (Fareed et al. 2006).  Even more compelling is the report that 
inhibition of calpain through transgenic over-expression of the endogenous calpain 
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inhibitor, calpastatin, attenuated muscle fiber atrophy associated with HS (Tidball & 
Spencer 2002).   
 The use of general protease inhibitors, like the Bowman-Birk inhibitor, a non- 
specific serine protease inhibitor known to inhibit a large number of proteases, has been 
reported to effectively attenuate the loss of muscle mass during HS (Morris et al. 2005).  
However, due to the broad spectrum of known and unknown targets of these drugs, 
such studies do little to help clarify important mechanisms.  Finally, rigorous isometric 
exercise interventions have been pursued as a means to ameliorate muscle atrophy 
during disuse (Haddad et al. 2006).  Although the exercise was able to fully blunt the 
increased expression of markers believed to be mediating muscle atrophy, including 
atrogin-1, MURF-1, and myostatin, the exercise failed to counteract disuse atrophy 
(Haddad et al. 2006).  Based on large bodies of work, summarized only briefly here, the 
conclusion is that the functional connections between the calpain, lysosomal, caspase, 
and ubiquitin-proteasome systems remain unknown (Taillandier et al. 1996; Taillandier 
et al. 2004). 
     
Inhibition of the Calpain System Reduces Muscle Fiber Atrophy 
 The calpain system is primarily comprised of three polypeptides: two Ca2+-
dependent proteases, calpain 1 and 2, along with an endogenous inhibitor of the two 
calpains; calpastatin.  In addition to the ubiquitous calpains 1 and 2, a third calpain, 
calpain 3, is expressed in skeletal muscle (Goll et al. 2003; Bartoli & Richard 2005). 
Calpain 1 and calpain 2 are heterodimers containing identical 28 kDa subunits and an 80 
kDa subunit that shares 55-66% homology between these two calpains (Goll et al. 
2003).  The terms µ-calpain (for calpain 1) and m-calpain (for calpain 2) where initially 
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used to refer to the micromolar and millimolar Ca2+ concentrations required for their 
activation.  Calpains 1 and 2 are activated at Ca2+ concentrations of 3 µM to 50 µM and 
400 µM to 800 µM, respectively, and undergo autolysis at Ca2+ concentrations of 50 µM 
to 150 µM and 550 µM to 800 µM, respectively (Goll et al. 2003).  Moreover, the 
activation of the calpains requires sustained elevations in Ca2+ concentrations on the 
order of many seconds to minutes, preventing calpain activation in response to 
contraction-associated increases in [Ca2+], which transiently reach 10s of µM (Murphy et 
al. 2006).  Although there is some controversy about the significance of the autolysis of 
the calpains, several studies report that auto-cleaved calpains 1 and 2 proteins are 
unstable and lose their proteolytic activity (Pal et al. 2001; Nakagawa et al. 2001; Li et al. 
2004a).   
Calpains 1 and 2 are primarily associated with the Z-lines of the myofibrils in 
skeletal muscle fibers and with the cytoskeleton and the plasma membrane in non-
muscle cells, and over 100 proteins have been shown to be cleaved by calpains in vitro 
(Goll et al. 2003).  Calpain activity has been reported to rapidly increase, within 12 
hours, in soleus muscles in response to HS (Enns & Belcastro 2006).  The ratio of 
calpain activity to calpastatin activity was also significantly elevated over the same 
period of time (Enns et al. 2007).  Moreover, a significant inverse relationship (r2 = 0.7) 
was demonstrated between the ratio of calpain 1/calpastatin activity and the level of 
desmin, a muscle-specific intermediate filament protein and known calpain substrate, 
although the decrease in the levels of desmin did not reach statistical significance during 
the HS (Enns et al. 2007).  The conclusion is that calpain activation, in particular calpain 
1, is an early event following muscle unloading and the resultant increase in the 
proteolytic potential of the calpain-calpastatin system contributes to the depletion of 
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myofibrillar proteins.  Despite this conclusion regarding the role of calpain 1 in muscle 
protein degradation during HS, the absence of calpain 1 in homozygous knock out mice 
has no apparent skeletal muscle phenotype (Azam et al. 2001).  In contrast, disruption of 
the calpain 2 gene is embryonically lethal (Zimmerman et al. 2000), and although calpain 
3 deficient mice exhibit smaller fibers than wild type littermates, calpain 3 activity is not 
increased during muscle atrophy (Bartoli & Richard 2005).   
Another approach to altering the calpain/calpastatin activity ratio is to increase 
calpastatin activity.  Transgenic mice over-expressing calpastatin 30- to 50-fold showed 
evidence for inhibition of calpain activity and the partial prevention of the muscle fiber 
atrophy induced by HS (Tidball & Spencer 2002).  However, no studies have 
investigated the effects of inhibition of the calpain system on skeletal muscle force 
generation, integrity of the force generating apparatus, or the ability of the muscle to 
withstand contraction-induced injury.  
 
Treatment with Deacetylace Inhibitors Increases Muscle Cell Size In Vitro and 
Induces Fiber Hypertrophy in Dystrophic Muscles In Vitro  
 In addition to approaches targeting protein degradation systems to ameliorate 
declines in skeletal muscles mass and function during disuse, modulation of positive or 
negative regulators of muscle growth also represents a strategy to alleviate such 
declines as well as to provide insights into the mechanisms underlying disuse atrophy.  
Recent investigations have used modulators of protein acetylation as a way to mediate 
hypertrophy in skeletal muscle (Minetti et al. 2006). The level of histone acetylation is an 
important means by which transcription is regulated.   
 Histones associate with DNA to form the complex chromatin structure into which 
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the DNA is organized and packaged within the nucleus of eukaryotic cells.  The 
modification of core histones by acetylation and deacetylation is of fundamental 
importance to conformational changes of the chromatin.  The core histone proteins are 
acetylated, by histone acetyltransferases, on lysine residues in the N-terminal tail and on 
the surface of the nucleosome core.  Upon acetylation, chromatin conformation is 
transformed into a more relaxed structure.  A relaxed chromatin structure allows the 
transcriptional machinery access to promoters increasing transcriptional activity (Clayton 
et al. 2006).  In contrast, the relaxation of the chromatin structure is reversed by the 
action of histone deacetylases, resulting in the condensation of chromatin conformation 
and gene silencing.  Histone deacetylases are also involved in the reversible acetylation 
of non-histone proteins.  Protein acetylation positively influences cell proliferation and 
differentiation in skeletal muscle.   
 Although the important targets underlying the positive effects of increased levels of 
protein acetylation in muscle are unknown, studies of C2C12 skeletal muscle cell lines 
showed that treatment with deacetylase inhibitors, including trichostatin A (TSA), 
valproic acid, and phenylbutyrate, resulted in the formation of larger myotubes compared 
with myotubes formed in cultures in the absence of the drug (Iezzi et al. 2002; Iezzi et al. 
2004).  Similar results were reported for human primary myoblast cultures providing 
motivation for the use of these drugs in vivo mice (Iezzi et al. 2002; Iezzi et al. 2004).  In 
addition, treatment of both mdx and alpha-sarcoglycan deficient mice, models of 
Duchenne and limb girdle type 2D muscular dystrophies, respectively, with TSA was 
reported to increase muscle fiber size, enhance exercise performance, improve muscle 
force generation, and decrease susceptibility to contraction-induced injury to levels 
comparable to those of wild type mice (Minetti et al. 2006).  Moreover, treatment with 
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TSA increased expression of markers of satellite cell activation and improved 
regeneration of injured muscles in wild type mice (Iezzi et al. 2002; Iezzi et al. 2004).   
The effects of deacetylase inhibitors appear to be mediated through the actions 
of a member of the transforming growth factor-beta (TGF-β) family of cytokines, 
follistatin.  Support for this hypothesis is provided by the observation that TSA treatment 
of C2C12 myoblasts increased follistatin expression while preventing follistatin 
transcription rendered myoblasts insensitive to TSA treatment.  Furthermore, treatment 
of C2C12 cells with follistatin inhibitors greatly reduced TSA-mediated myoblast fusion 
(Iezzi et al. 2002; Iezzi et al. 2004).  In addition, the beneficial effects of TSA treatment in 
mdx mice (Minetti et al. 2006) and the enhanced regeneration observed following TSA 
treatment in wild type mice (Iezzi et al. 2002; Iezzi et al. 2004) were, in both cases, 
accompanied by increased follistatin expression.  Although the mechanism by which 
follistatin acts is not known, a recent study presented compelling evidence that the 
skeletal muscle hypertrophy induced by follistatin over-expression was dependent at 
least in part through the activation of satellite cells (Gilson et al. 2009).   
One pathway by which follistatin may influence satellite cell activation is through 
its interaction with another TGF-β family member, myostatin (Lee & McPherron 2001).  
Myostatin is a negative regulator of skeletal muscle mass that appears to act, at least in 
part, by inhibiting the proliferation, differentiation, and self-renewal of myoblasts (Thomas 
et al. 2000; Taylor et al. 2001; McCroskery et al. 2003), and a reduction in myostatin 
levels, achieved either through inactivation of the myostatin genes or through postnatal 
inhibition of myostatin, results in dramatic increases in skeletal muscle mass  (Grobet et 
al., 2003; McPherron et al., 1997; McPherron and Lee, 1997; Whittemore et al., 2003).  
Despite a known role of follistatin in inhibiting myostatin in vivo (Lee & McPherron 2001), 
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over-expression of follistatin in myostatin-deficient mice results in additional muscle 
hypertrophy on top of the increases induced by the lack of myostatin (Gilson et al. 2009) 
indicating the ability of follistatin to act in a myostatin-independent manner.  The ability of 
myostatin inhibition, follistatin over-expression, or treatment with deacetylase inhibitors 
to prevent the loss of muscle mass during hindlimb suspension has not been explored, 
but atrophy was not prevented in myostatin deficient mice exposed to HS (McMahon et 
al. 2003).  In fact, following 7 days of HS, muscle mass decreased to a greater extent in 
the myostatin deficient mice compared with their wild type littermates (McMahon et al. 
2003). 
 
Study Aims and Hypotheses 
The purpose of this thesis is to investigate the impact of manipulating pathways 
that modulate either muscle protein degradation, through the inhibition of the calcium-
activated protease calpain, or muscle growth pathways, through the inhibition of 
deacetylase activity, to ameliorate the declines in skeletal muscle mass and force 
generating capacity that occur in response to disuse.  Using the widely recognized HS 
model of muscle disuse in mice, the overall hypothesis that inhibition of either calpain 
activity or protein deacetylase activity would ameliorate the development of disuse-
induced muscle atrophy and weakness was tested.  To address this hypothesis two 
experimental chapters are presented.   
For Chapter 2, a colony of transgenic mice was generated that over-expressed 
calpastatin by ~20-fold in a muscle specific manner.  Calpastatin over-expressing 
transgenic mice (cp mice) and wild type littermates (wt mice) were subjected to 3, 9, or 
14 days of HS.  After a given period of HS, soleus and EDL muscles were removed and 
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evaluated for mass; isometric contractile properties, passive resistance to stretch, and 
susceptibility to lengthening-contraction induced injury measured in vitro; individual fiber 
cross-sectional areas determined from histological samples; and disruption of the 
underlying sarcomere structure through analysis of electron micrographs.   
In Chapter 3, a study is described in which C57BL/6 control mice were treated 
with either the deacetylase inhibitor trichostatin A (TSA) or vehicle during a period of 14 
or 21 days of HS.  Based on findings in Chapter 2 that 14 days of HS had no effect on 
mass or force generation of the EDL muscles of mice, we concentrated our studies in 
Chapter 3 on the soleus muscle.  Again, following HS, muscles were removed and 
evaluated for mass, isometric contractile properties, susceptibility to lengthening-
contraction induced injury, and individual fiber cross-sectional areas.   
The results of Chapter 2 indicate that calpain activity is critical mediator of the 
disruption of the sarcomere structure leading to decreased isometric force generating 
capability induced in soleus muscles during unloading associated with HS.  In contrast, 
inhibition of calpain activity does not prevent the loss of soleus muscle mass associated 
with unloading.  Our findings in Chapter 3 showed that treatment with TSA provides no 
protection from the substantial decrease in specific force induced by unloading, but 
individual fiber CSAs were 30-40% larger in TSA treated mice compared with those in 
vehicle treated animals after 21 days of HS.  Thus, calpain inhibition may be an 
important and effective target for preventing muscle weakness during disuse, by 
minimizing proteolytic damage to the force generating apparatus, especially in 
combination with additional therapies aimed at preventing muscle atrophy by stimulating 
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INHIBITION OF CALPAIN PREVENTS MUSCLE WEAKNESS AND DISRUPTION OF 
SARCOMERE STRUCTURE DURING HINDLIMB SUSPENSION 
 
Summary  
Unloading skeletal muscle results in atrophy and a decreased ability of the 
remaining muscle to generate force.  Reduced atrophy has been reported when calpain 
activity is inhibited during unloading, but the impact on force generating capability has 
not been established.  Our hypothesis is that endogenous inhibition of the calpain 
system, through muscle specific over-expression of calpastatin, prevents the disruption 
of sarcomere structure and the decreased specific force (kN/m2) observed with 
unloading.  Wild type (wt) and calpastatin over-expressing transgenic (cp) mice were 
subjected to hindlimb suspension (HS).  Following 3, 9, or 14 days of HS, soleus and 
extensor digitorum longus (EDL) muscles were removed from anesthetized mice and 
contractile properties were measured in vitro.  EDL muscles were not affected by HS in 
wt or cp mice.  Compared with soleus muscles of non-suspended control mice, soleus 
muscles of wt mice showed a 25% decline in mass after 14 days of HS while maximum 
isometric force (Po) decreased by 40%, resulting in a specific Po that was 35% lower 
than control values.  Over the same time period, muscles of cp mice demonstrated 25% 
declines in both mass and Po but no change in specific Po.  Consistent with the 
preservation of isometric force generating capability, soleus muscles of cp mice 
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maintained a high degree of order in sarcomere structure, in contrast to muscles of wt 
mice that demonstrated misalignment of z-lines and decreased uniformity of thick 
filament lengths following HS.  Maximally activated muscles were also exposed to two 
stretches of 30% strain relative to fiber length.  The magnitude of the deficit in force 
induced by the stretches increased with the duration of HS, but was not different for 
muscles of cp and wt mice.  Thus, while isometric force generating capability and 
sarcomere structure were preserved during HS by calpain inhibition, the susceptibility to 
injury induced by lengthening contractions was not reduced.  We conclude that inhibition 
of calpain activity during unloading preserves sarcomere structure such that the 
isometric force generating capability is not diminished, while the effects of unloading on 




Skeletal muscle atrophy and weakness are prominent features of diseases 
including cancer (Russell et al. 2009), sepsis (Williams et al. 1999), and diabetes (Price 
& Mitch 1998), as well as during bed rest (Widrick et al. 1997) and during the muscle 
unloading associated with travel to space (Gardetto et al. 1989; Widrick et al. 1999).  
The atrophy has been attributed to an imbalance created by factors that control protein 
synthesis and those that control protein degradation (Thomason et al. 1989).  Several 
proteolytic systems contribute to the turnover of muscle proteins, including the lysosomal 
system, the caspase system, the ubiquitin-proteasome system, and the calpain system 
(Goll et al. 2008).  An important role for the calpain system in skeletal muscle atrophy 
has been implicated by several investigators (Taillandier et al. 1996; Spencer et al. 
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1997; Enns & Belcastro 2006), but clear conclusions have not emerged.  While some 
reports indicated increases in calpain mRNA in skeletal muscle during unloading by 
hindlimb suspension (HS) (Taillandier et al. 1996) or spinal cord transaction (Haddad et 
al. 2003), others showed no change in calpain mRNA with unloading by HS (Stevenson 
et al. 2003) or spaceflight (Ikemoto et al. 2001).  Regardless, mRNA levels are not 
indicative of protein concentrations or activity (Croall & DeMartino 1991).  Changes in 
calpain activity have been explored by isolating calpain from muscles following exercise 
or injury and incubating the protein with known substrates (Arthur et al. 1999; Reid & 
Belcastro 2000), but this approach ignores both endogenous calpain inhibitors present in 
the muscle in vivo and the intracellular calcium concentrations critical for calpain 
activation.  Some of the aforementioned pitfalls were circumvented in studies using 
transgenic mice that over-expressed calpastatin, an endogenous inhibitor of calpain 
(Tidball & Spencer 2002).  After 10 days of HS, the calpastatin over-expressing mice 
showed reduced muscle fiber atrophy and prevented the shift to faster myosin heavy 
chain isoforms typical of inactivity (Tidball & Spencer 2002).   
In addition to inducing muscle atrophy, unloading also disrupts force generating 
capability, which decreases muscle performance and increases susceptibility to 
contraction-induced injury (Gardetto et al. 1989; Widrick et al. 1999; Trappe et al. 2009).  
Decreased muscle force generating capacity may provide an explanation for the lack of 
success of exercise countermeasures during muscle unloading in rats and humans 
(Haddad et al. 2006; Trappe et al. 2009). Our preliminary studies showed weakness of 
muscles following a period of HS (data not shown), defined as a decrease in maximum 
isometric force in excess of what can be explained by atrophy, i.e. a decreased specific 
force (kN/m2).  To elucidate the contribution of the calpain system to the development of 
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both atrophy and weakness during unloading induced by HS, we analyzed the time 
course of the effects of in vivo inhibition of calpain by utilizing a line of transgenic mice 
with muscle-specific over-expression of calpastatin (Otani et al. 2004).  Our working 
hypothesis is that the decreased specific force observed following the removal of weight 
bearing is due to the disruption of the underlying sarcomere structure by the calcium-
dependent calpain system.  Specifically, we hypothesized that following various periods 
of HS, atrophy, weakness, and susceptibility to lengthening contraction-induced injury 
would be less severe for muscles of transgenic calpastatin over-expressing (cp) mice 
than for muscles of wild type (wt) littermates.  We further hypothesized that underlying 
sarcomere structure would be maintained during HS in cp but not wt mice.         
 
Methods 
All experiments were performed on 4- to 5-month old specific pathogen free 
(SPF) male C57BL/6 mice from a colony of transgenic calpastatin over-expressing (cp) 
mice and wild type (wt) littermates bred in house in the University of Michigan Unit for 
Laboratory Animal Medicine.  All procedures were approved by the University of 
Michigan Committee for the Use and Care of Animals.  A total of 26 cp and 29 wt mice 
were randomly assigned to one of four groups: experimental mice exposed to hind limb 
suspension (HS) for periods of 3, 9, or 14 days and non-suspended (control) mice that 
maintained normal levels of activity.  During all operative procedures, mice were 
anesthetized with intraperitoneal injections of Avertin™ at a dose of 400 mg/kg 
tribromoethanol, with supplemental doses provided to maintain an adequate level of 





Breeding pairs of cp mice were obtained as a kind gift from Dr. Kenneth Polonsky 
at Washington University School of Medicine, St. Louis, MO.  From these founder mice, 
we established an internal colony for this study.  The transgene DNA was targeted to 
skeletal muscle using the murine muscle-specific creatine kinase promoter followed by a 
bovine growth hormone polyadenylation signal sequence (Otani et al. 2004).  
 
Hindlimb Suspension   
HS is a widely used method for unloading rodent hind limbs.  Our method of HS 
was modified from that originally described by Morey (Morey 1979).  Briefly, surgical 
tape (3M, Two Harbors, MN) was used to wrap the tail of each animal against a rigid 
metal wire piece with a manually bent upper hook connected to a rotating pulley.  The 
tape was lightly soaked with liquid suture VetBond (3M, Two Harbor, MN) to create an 
instant cast.  Care was taken to prevent any VetBond from dripping onto the animal’s 
tail.  During the casting process, mice were briefly restrained in a small terrycloth wrap 
with the tail exposed.  Since the entire process of preparing the tail was completed within 
two minutes, no anesthetic was required during the procedure.  After the tape and metal 
piece were attached, mice were released into a cage until the glue was dry. Once the 
tape hardened, the hind legs of the mice were lifted slightly off the floor of the cage by 
connecting the pulley to a metal rod inside the suspension cage.  The rotating pulley 
system enabled mice to move from one end of the cage to the other with a full 360° 
range of motion and obtain food and water freely.  Mice were observed daily for changes 




In Vitro Muscle Contractile Properties   
Under deep anesthesia, soleus and extensor digitorum longus (EDL) muscles of 
one limb were isolated from control mice, and from mice exposed to 3, 9, or 14 days of 
HS.  5-0 silk suture ties were secured around the distal and proximal tendons, and the 
muscles were carefully removed and placed in a horizontal bath containing buffered 
mammalian Ringer solution (composition in mM: 137 NaCl, 24 NaHCO3, 11 glucose, 5 
KCl, 2 CaCl2, 1 MgSO4, 1 NaH2PO4, and
 0.025 turbocurarine chloride) maintained at 25 
°C and bubbled with 95% O2 / 5% CO2 to stabilize pH at 7.4.  One tendon of the
 muscle 
was tied securely to a force transducer (model BG-50, Kulite Semiconductor Products, 
Leonia, NJ) and the other tendon to the lever arm of a servomotor (model 305B, Aurora 
Scientific, Richmond Hill, ON, Canada).  The contralateral soleus and EDL muscles were 
removed and prepared for future analyses of protein levels and activities or sarcomere 
structure.  After removal of the muscles, mice were euthanized with an overdose of 
anesthetic and administration of a bilateral pneumothorax. 
For measurement of isometric contractile properties, muscles were stimulated 
between two stainless steel plate electrodes.  The voltage of single 0.2-ms square 
stimulation pulses and, subsequently, muscle length (Lo) were adjusted to obtain 
maximal twitch force.  Muscle length was measured with calipers.  With the muscle held 
at Lo, the force developed during trains of stimulation pulses
 was recorded, and 
stimulation frequency was increased until the maximum isometric tetanic force (Po) was 
achieved.  For EDL muscles, 300-ms trains of pulses were used, and 900-ms trains were 
used for soleus muscles.  A stimulus frequency of 140 Hz was typically needed to 
achieve Po for both EDL and soleus muscles
 of cp mice, whereas frequencies of 120 and 
130 Hz elicited Po for EDL and soleus muscles, respectively, of wt animals.
  For each 
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muscle, optimum fiber length (Lf) was calculated by
 multiplying Lo by previously 
determined Lf/Lo ratios for EDL
 and soleus muscles of 0.45 and 0.71, respectively 
(Brooks & Faulkner 1988). 
Following assessment of the maximum isometric tetanic forces, EDL and soleus 
muscles were exposed to a single constant velocity stretch without activation (passive 
stretch) of 30% strain relative to Lf to obtain a measurement of the passive extension 
properties of the muscles.  The velocity of the stretch was 2 Lf/s.  The peak force 
achieved during the stretch was recorded.  Each passive stretch was followed by a 
single maximum isometric contraction to verify that the stretch did not induce any injury.  
Following the passive stretch, each muscle was exposed to two additional 30% stretches 
also at 2 Lf/s initiated from the
 plateau of an isometric contraction at the stimulation 
frequency that elicited Po.  Prior to the stretch, EDL and soleus muscles
 were held 
isometric for the first 100 or 300 ms, respectively, of each contraction to allow near 
maximal activation, and stimulation was terminated at the end of the lengthening ramp.  
One minute of rest was allowed before the second lengthening contraction was initiated 
and Po was measured once again 1 minute after the second lengthening contraction.  
The force deficit induced by the two lengthening contractions was calculated as the 
difference between the isometric forces measured before and after the stretches, 
expressed as a percentage of the force before the stretch.   
After the force measurements, muscles were removed from the bath, the tendons 
were trimmed, and the muscle was blotted and weighed.  Muscles were quick frozen in 
isopentane cooled with liquid nitrogen and stored at -80 °C for subsequent histological 
analyses.  Total muscle fiber cross-sectional area (CSA) was calculated by dividing the 
muscle mass by the product of Lf and the density of
 mammalian skeletal muscle, 1.06 
31 
 
g/cm3.  Specific Po (kN/m
2) was calculated by dividing Po by total fiber CSA for each 
muscle. 
 
Myosin ATPase Activity  
Frozen cross sections of 10 µm thickness were cut from the widest portion of the 
belly of each muscle.  Cryosections were placed on microscope slides and incubated at 
varyious pH conditions to allow identification of Type 1 and Type 2 on the basis of 
myofibrillar ATPase activity, as previously described (Brooke & Kaiser 1970).  Stained 
sections were visualized on a microscope (Leitz Laborlux, Leica; Wetzlar, Germany) and 
captured with a video camera (Diagnostic Instruments; Sterling Heights, MI), and the 
image analyzing software ImageJ was used to calculate individual fiber CSAs.  For each 
muscle, individual fiber CSAs were evaluated from two to three fields at 20x 
magnification, with each field containing ~50 fibers.  Fields were chosen randomly from 
the central portion of the muscle avoiding fields that reached the edge of the section.  
Images from sections of soleus muscles from n = 4-6 were analyzed for suspended and 
control wt and cp mice.  Consequently, single fiber areas were measured for 400-600 
fibers for each experimental group.  
 
Calpastatin Western Blot   
Total protein extracts from soleus muscles were prepared by homogenizing 
muscles in CytoBuster Protein Extraction System and protease blocking cocktails III and 
VIII from Calbiochem.  Protein was resolved by SDS-PAGE and transferred to 
nitrocellulose membranes (Calbiochem).  The membranes were blocked overnight at 4°C 
with 5% nonfat milk in phosphate-buffered saline containing 0.1% Tween 20.  The 
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membranes were probed with polyclonal anti-CAST (Calbiochem, La Jolla, CA).  
Horseradish peroxidase-conjugated secondary antibodies were obtained from Santa 
Cruz BioTechnology Inc. (Santa Cruz, CA) and reagents for enhanced 
chemiluminescence purchased from Thermo Scientific (Rockford, IL). 
 
Calpastatin Inhibitory Activity Analysis 
Total protein extracts from soleus muscles were prepared by homogenizing 
muscle in CytoBuster Protein Extraction System.  To verify the inhibitory capacity of the 
increased calpastatin protein levels, muscle homogenates from cp and wt mice soleus 
muscles were analyzed with the InnoZyme Calpain 1 and 2 Activity Kit from Calbiochem 
(La Jolla, CA).  This assay detects calpain activity by measuring the fluorescence 
produced upon cleavage of a calpain specific site on a fluorescent dye, (DABCYL)-
TPLK|SPPPSPR-(EDANS).  Fluorescence was visualized using the FlexStation3 plate 
reader at the Center for Chemical Genomics in the Life Sciences Institute at University of 
Michigan.  
 
Electron Microscopy   
Soleus muscles from control mice and mice that were exposed to 14 days of HS 
were removed, pinned at a fixed taut length, and immediately placed in 0.1 M 
cacodylate-buffered Karnovsky's fixative solution (3% glutaraldahyde and 3% 
formaldehyde).  After the tissues were fixed, each muscle was divided into three parts to 
allow both cross and longitudinal sections and fixed for 4 hours at 40 ºC, pH 7.4.  The 
muscles were then washed overnight in rinsing cacodylate buffer, post-fixed in a 
buffered solution of 1% osmium tetroxide, and dehydrated through a graded ethanol 
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series.  Each section was propylene oxide embedded in epoxy resin and polymerized for 
3 days at 450 ºC and 1 day at 600 ºC.  Sections were cut on a Sorvall MT5000 
ultramicrotome (DuPont, Newton, CT, USA) and stained with 1% Toluidine Blue for light 
microscopic evaluation, and ultra-thin sections were obtained by cutting the specimens 
with a diamond knife on the same ultramicrotome and post-staining in 1% uranyl acetate 
and lead citrate.  These sections were examined with a Philips CM-10 transmission 
electron microscope (Philips Electronic Instruments Co., Mahwah, NJ, USA) operating at 
60 kV.  Micrographs were analyzed using ImageJ to quantify the width of the A-bands 
through measurements of the lengths of individual thick filaments.  For control mice, 
twenty filaments were measured from two regions of muscles from two different animals, 
and for mice exposed to 14 days of HS, three regions of muscles from four different mice 
were analyzed for a total of 640 thick filaments measured. 
 
Statistics   
All data are presented as means ± 1 S.E.M. unless indicated otherwise.  The 
effects of genotype (wt, cp) and duration of unloading (none, 3, 9, 14 days) on muscle 
mass, Po, specific Po, peak force during passive stretches, force deficits following 
lengthening contractions, single fiber CSAs, and thick filament lengths were determined 
by two factor analysis of variance (ANOVA) with a level of significance at P < 0.05.  









Phenotype of Calpastatin Over-Expressing Mice   
Similar to the levels of calpastatin over-expression previously reported in pooled 
hind limb muscle by Polonsky’s group (Otani et al. 2004) calpastatin levels were 
increased ~20 fold in soleus muscles of cp compared with wt mice (Fig. 2.1A).  The 
ability of this level of calpastatin over-expression in the soleus muscles to inhibit calpain 
activity was demonstrated using the fluorometric calpain activity assay.  The sensitivity 
of this assay was not sufficient to detect the endogenous calpain activities in the 
extremely small volume of homogenates obtained from individual soleus muscles.  Thus, 
our approach was to assess the ability of endogenous calpastatin activity in the muscle 
homogenates to inhibit known concentrations of exogenous calpain (5 µg/ml).  When 
exogenous calpain was added to wt muscle homogenates, cleavage of the fluorescent 
protein increased substantially (Fig 2.1B).  In contrast, the cp muscle homogenates 
demonstrated no calpain activity above baseline even when 5 µg/ml exogenous calpain 
was added to the cp muscle homogenates (Fig 2.1B), indicating that the muscles of cp 
mice possessed substantial capacity for inhibiting calpain activity.   
Despite the high levels of calpastatin in the muscles of cp mice, the body masses 
of the cp mice, 28.3 ± 0.6 grams, and wt littermates, 28.5 ± 0.4 grams, were not 
different, nor were the muscle masses for soleus or EDL muscles from control cp and wt 
mice (Fig. 2.1C).  Consistent with the similarity of muscle masses between cp and wt 
mice, Po was not different for either soleus or EDL muscles of control cp and wt mice 
(data not shown).  When normalized by total muscle fiber CSA, specific Po values for 
EDL muscles of cp and wt mice were also not different, but soleus muscles of cp mice 
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showed a small amount of weakness as reflected in a specific Po that was just over 10% 
lower for muscles of cp compared with wt mice (Fig. 2.1D).  Finally, with respect to the 
susceptibility to lengthening contraction-induced injury, maximally activated soleus and 
EDL muscles of both cp and wt mice suffered a deficit in isometric force of ~8% following 
two lengthening contractions of 30% strain, with no differences between muscles or 
groups of mice (Fig. 2.1E). 
 
Response to Hind Limb Suspension.   
Body Mass. All mice used in this study were weighed prior to HS and at the point 
when they were sacrificed.  Although most mice lost a small amount of mass during the 
period of HS, some mice actually showed slight gains, with no difference between the cp 
and wt mice.  Moreover, the loss in body mass was not progressive, that is, mice 
suspended for 14 days did not show a greater loss of mass than those suspended for 3 
or 9 days.  Overall, for the 40 mice that experienced any period of HS, the average 
change in weight was a loss of 4.2% ± 0.8%. 
Soleus Muscle Atrophy. Compared with control muscles, 14 days of HS induced 
a decline in soleus muscle wet mass of 25% that was not different for cp and wt mice, 
although the decrease became statistically significant after only 3 days for muscles of wt 
mice, compared with 14 days for cp mice (Fig. 2.2).  Similarly, analysis of the individual 
single fiber CSAs showed no overall effect of genotype on the CSA of either type 1 (P = 
0.65) or type 2 (P = 0.12) fibers, either in control mice or following HS (Fig 2.3).  Analysis 
of the effect of HS on CSA of type 1 fibers showed a trend (P = 0.08) for a decline by 
Day 9 and a significant decline (P = 0.02) of 30% by Day 14.  In contrast, while the CSAs 
of type 2 fibers were trending downward for soleus muscles of both cp and wt mice, the 
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decrease in CSA compared with control muscles of ~12% after 14 days did not reach 
statistical significance (P = 0.18).  
Soleus Muscle Isometric Contractile Properties. With the loss of soleus muscle 
mass and fiber CSA, a coincident loss in force was observed (Fig. 2.4).  Whereas 
muscle mass showed only a trend for a further decrease beyond 3 days of HS for wt 
mice, the decrease in Po for wt mice continued to progress out to Day 14, at which point 
Po was 40% lower than the value for soleus muscles of control wt mice.  Consistent with 
the progressive loss of force with HS by soleus muscles of wt mice, along with no further 
decrease in mass after Day 3, specific Po declined throughout the entire duration of HS.  
Although the 6.5% decrease in specific Po after 3 days of HS was not statistically 
significant, by 9 days, specific Po was 28% lower than the value for muscles of control wt 
mice (Fig. 2.5).  Specific Po continued to decline such that, after 14 days of HS, the value 
was decreased by 35% compared with the control value.  In contrast to the profound 
weakness induced by HS in soleus muscles of wt mice, the specific Po for soleus 
muscles of cp mice exposed to HS showed no decrease compared with the value for 
soleus muscles of control cp mice even after 14 days of HS (Fig. 2.5).  
Sarcomere Structure.  The maintenance of isometric force generating capacity in 
the muscles of cp mice suggested there was preservation of the underlying myofibrillar 
structure in the cp mice.  Therefore, sarcomere ultrastructure in muscles of cp and wt 
mice was examined by electron microscopy (Fig. 2.6).  Control muscles from both wt 
and cp mice demonstrated a highly ordered array of well-aligned sarcomeres with great 
consistency of A-band widths (Figs. 2.6A, 2.6C).  Following 14 days of HS, a clear loss 
of the sarcomeric organization within muscles of wt mice was observed (Fig. 2.6B).  Also 
clear visually was an increased variability in the width of the A-bands.  In contrast, in 
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muscles of cp mice exposed to 14 days of HS, the alignment of sarcomeres and the 
uniformity of the A-band widths were maintained to a much larger degree than in wt mice 
(Fig 2.6D).  These observations were supported by quantitative analysis of individual 
thick filament lengths (Fig. 2.7).  In control muscles, thick filament lengths were highly 
uniform and were not different for soleus muscles of wt and cp mice.  Compared with the 
uniformity in the lengths of the thick filaments in sarcomeres of control muscles, HS 
resulted in a substantial increase in muscles of wt mice in the variability of the thick 
filament lengths (Fig. 2.7).  Although neither the mean nor median thick filament lengths 
changed for muscles of wt mice following 14 days of HS, sarcomeres contained 
coexisting combinations of short and long thick filaments, resulting in a doubling of the 
standard deviation.  In contrast, soleus muscles from the cp mice maintained roughly the 
same uniformity in thick filament lengths even after 14 days of HS (Fig. 2.7). 
Passive Resistance to Stretch.  The decreased uniformity of thick filament 
lengths following HS for wt mice was accompanied by a substantial decrease in the 
resistance to passive stretch, as reflected in the lower peak force during the stretch (Fig. 
2.8).  Moreover, in cp mice, peak passive force was unaffected by HS consistent with the 
maintenance in these muscles of a uniformity of thick filament lengths.   
Susceptibility to Contraction Induced Injury.  Two 30% lengthening contractions 
of maximally activated soleus muscles caused significant deficits in isometric force that 
worsened progressively after periods of HS.  For wt mice, the amount of injury, as 
measured by the force deficit one minute after the second lengthening contraction, 
increased steadily to reach a level nearly 4-fold greater than that of control muscles by 
Day 14 (Fig. 2.9).  Soleus muscles of cp mice also demonstrated a marked increase in 
susceptibility to injury after HS such that after 14 days the force deficit induced by 
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lengthening contractions for muscles of cp mice was not different from that induced in wt 
mice (Fig. 2.9). 
EDL Muscle Mass and Contractile Properties.  The effects of HS on EDL 
muscles were minimal.  In wt mice, EDL muscle mass showed a transient decrease of 
20% in wt mice at Day 3, but mass recovered by Day 9 and remained unchanged during 
the remainder of the period of HS (Fig 2.10).  The small decrease in mass was not 
accompanied by a decrease in force generation, as neither Po nor specific Po was 
affected by HS.  For EDL muscles of cp mice, both the mass and the contractile 
properties remained unchanged throughout the 14 days of HS (Fig 2.10). 
 
Discussion 
Progressive skeletal muscle atrophy and weakness are among the primary 
effects of skeletal muscle unloading, immobilization, and spaceflight (Gardetto et al. 
1989; Tischler et al. 1993; Riley et al. 1995; Widrick et al. 1999).  Previous work showed 
that inhibition of the protease calpain, through over-expression of calpastatin in a 
transgenic mouse model, reduced the amount of muscle fiber atrophy in response to 10 
days of HS (Tidball & Spencer 2002), but the impact of calpain inhibition on skeletal 
muscle function has not previously been addressed.  The major finding of the present 
study was that in contrast to the progressive decrease with HS in maximum isometric 
specific force exhibited by soleus muscles of wt mice, the development of muscle 
weakness was completely prevented during 14 days of HS when calpain was inhibited 
by increased in vivo expression of calpastatin.  The protection of the muscles of cp mice 
from developing weakness with unloading is consistent with our hypothesis that the 
decreased specific force observed following the removal of weight bearing is due to the 
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disruption by the calpain system of the underlying sarcomere structure.  Further support 
for this hypothesis was provided by a second key finding in the present study that the 
maintenance of specific Po in cp mice during HS was accompanied by a striking 
preservation of sarcomere ultrastructure compared with the disorganization in sarcomere 
structure observed after 14 days of HS in wt mice.  Our observation that calpain 
inhibition in our transgenic model did not prevent atrophy after 14 days of unloading 
likely reflects the longer time period of unloading in our study compared to the study of 
Tidball and Spencer (Tidball & Spencer 2002) who studied mice exposed to 10 days of 
HS.  We similarly showed no significant loss of soleus muscle mass at 9 days in cp mice 
as well as a 13% further loss of mass between 9 and 14 days.   
Mice deficient in either of two muscle-specific ubiquitin ligases, Muscle RING 
Finger 1 (MuRF1) or Muscle Atrophy F-box (MAFbx, also known as atrogin-1), have also 
displayed an attenuation of muscle atrophy leading to the conclusion that the ubiquitin-
proteasome system is required for muscle atrophy in response to disuse (Bodine et al. 
2001a), although those experiments employed denervation rather than HS to trigger 
atrophy in the muscles.  The proteasome has been shown to degrade purified actin and 
myosin, but specific interactions between myofibrillar proteins appear to protect intact 
myofibrils from ubiquitin-dependent degradation, with the rate-limiting step in the 
degradation of myofibrillar proteins proposed to be their dissociation from the myofibril 
(Solomon & Goldberg 1996).  One hypothesis is that cleavage of sarcomeric proteins by 
calpain may be necessary to provide substrate for the ubiquitin-proteasome system 
(Kandarian & Stevenson 2002).  An important role of calpain in cytoskeletal remodeling 
during the early phase of the muscle response to alterations in loading is supported by 
several investigations (Enns & Belcastro 2006; Vermaelen et al. 2007), and the 
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preservation in the present study of sarcomere structure and specific Po under 
circumstances when calpain was inhibited during unloading provides strong support for 
the conclusion that calpain targets the force generating infrastructure during disuse.  
Despite substantial support for the coordinated action of calpain and the ubiquitin-
proteasome system to mediate muscle atrophy in response to unloading, the present 
finding that inhibition of calpain during 14 days of HS did not prevent atrophy coupled 
with the findings that following 14 days of denervation, muscle mass decreased 30% and 
20% in mice deficient in MuRF1 or MAFbx, respectively (Bodine et al. 2001b), suggests 
that the inhibition or even prevention of protein degradation may be insufficient to protect 
muscle completely from a loss in mass during unloading.  Alternate or additional 
approaches targeting the enhancement of protein synthesis and muscle growth (Bodine 
et al. 2001c) rather than the inhibition of protein degradation may be necessary to fully 
counteract the atrophy associated with disuse.      
One known calpain substrate and hypothesized in vivo target of calpain is the 
giant sarcomeric protein titin (Goto et al. 2003; Lim et al. 2004; Raynaud et al. 2005; 
Udaka et al. 2008; Goll et al. 2008). Titin contains high-affinity calpain binding sites 
where the protein is cleaved (Raynaud et al. 2005). Titin is well recognized as the main 
determinant within muscle fibers of passive tension (Horowits et al. 1986; Funatsu et al. 
1990) and may serve as a regulator of thick filament length during sarcomere assembly 
(Whiting et al. 1989; Trinick 1994). Recently, Udaka and colleagues (Udaka et al. 2008) 
reported that muscle disuse, achieved through immobilization of a limb by casting, 
induced changes within sarcomeres that were correlated with the proteolytic cleavage of 
titin.  Among the responses to immobilization that were associated with a preferential 
loss of titin were decreased mean thick filament length, decreased uniformity of thick 
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filament length, decreased maximum isometric specific force, and decreased passive 
force (Udaka et al. 2008).  We show here strong evidence that the changes in passive 
force and increased variability of thick filament length can be prevented in muscles 
where calpain activity is inhibited providing in vivo evidence for the role of calpain 
mediated protein cleavage in these functional changes that occur during HS.  
Furthermore, the maintenance of passive tension and the preservation of the uniformity 
in thick filaments lengths for muscles of cp mice, in combination with the results by 
Udaka and colleagues, are consistent with the hypothesis that calpain targets titin and 
the inhibition of calpain may protect against loss in titin function, at least to some extent.  
An additional calpain substrate that may be targeted during HS is the intermediate 
filament protein desmin (Enns et al. 2007). Desmin functions to maintain sarcomeres 
within adjacent myofibrils in register, and deficiency of desmin results in muscle 
weakness (Sam et al. 2000).  Our electron micrographs showed a loss following HS of 
the alignment of sarcomeres in the muscles of wt mice along with the substantial 
reduction in specific Po.  The observation that, in cp mice, specific Po was unaffected by 
HS and sarcomere alignment was maintained is consistent with the hypothesis that 
additional proteins responsibility for sarcomere integrity, such as desmin, may also be 
spared by the inhibition of calpain.  Collectively, these findings provide evidence for a 
model in which muscle unloading increases in vivo calpain mediated cleavage 
sarcomere proteins, possibly titin and desmin, leading to alterations within the 
sarcomere that decrease force generating capacity.    
A surprising observation in the present study was that, although muscles of cp 
mice maintained specific force during HS, the muscles of cp mice were not protected to 
any great extent from the increased susceptibility to lengthening contraction-induced 
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injury observed during HS.  In many disease states such as muscular dystrophy and 
aging, the increased susceptibility to contraction induced injury is tightly associated with 
muscle weakness (Brooks & Faulkner 1996; Consolino & Brooks 2004).  Our results 
showed that the preservation of sarcomeric structure and force production afforded by 
the inhibition of calpain was not accompanied by maintenance of the ability to withstand 
the additional stress associated with lengthening contractions.  These data support the 
conclusion that the increased susceptibility to contraction-induced injury and muscle 
weakness induced by HS are likely occurring through distinct cellular mechanisms and 
the effect of HS to increase contraction-induced injury is not mediated by calpain-
dependent proteolytic activity.   
Our data substantiate the common finding that the EDL muscle, which is 
comprised primarily of type 2 fibers, is minimally affected by unloading (Darr & Schultz 
1989; Thompson & Shoeman 1998; Fitts et al. 2001).  Although it is generally accepted 
that fast muscles are less sensitive to disuse-induced atrophy than slow muscles 
(Baldwin & Haddad 2002), the mechanisms underlying these differences between fast 
and slow muscles remain an area of active investigation.  Fast muscles may be less 
susceptible than slow muscles to HS due to differential activation of downstream cellular 
responses to HS in type 1 and type 2 fibers.  Previous work demonstrated that slow 
soleus muscles exhibited increased calpain activation during atrophy within 12 hours of 
HS, whereas a significant increase in calpain activity was not observed in fast 
gastrocnemius muscles until the muscles had been unloaded for more than 3 days 
(Enns & Belcastro 2006).  Moreover, 5 days of hindlimb immobilization resulted in 
increased levels of both autolyzed calpain 1 and autolyzed calpain 2 in soleus muscles 
but no change in either calpain 1 or 2 in fast plantaris muscles (Vermaelen et al. 2007).  
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Thus, the sensitivity of type 1 fibers to disuse atrophy may be related to fiber-type 
specificity of the activation pattern of calpain following HS.  Finally, the lack of atrophy of 
EDL muscles during HS may be a consequence of the small amount of loading of the 
muscles provided by flexing the ankle and lifting the hind paws against gravity, rather 
than a complete insensitivity of type 2 fibers to disuse atrophy.  Regardless of the 
precise mechanisms for the different response of slow and fast muscles, our studies 
demonstrate that if activation of calpain is inhibited in slow muscle, many of the effects of 
HS on muscle contractile function and sarcomeric structure can be prevented.     
In summary, this study provides clear evidence that inhibition of the calpain 
system during HS preserves sarcomere structure and prevents the development of 
muscle weakness in soleus muscles.  These findings support our working hypothesis 
that the decreased specific force observed following the removal of weight bearing is 
due to the disruption of the underlying sarcomere structure by calpains.  Protection from 
sarcomeric disruption by the inhibition of calpain, perhaps through the inhibition of 
cleavage of sarcomeric proteins such as titin, is also supported by our observation of the 
maintenance of passive tension and uniformity of thick filament lengths in soleus 
muscles of cp mice exposed to 14 days of HS.  Finally, our findings that the loss of 
soleus muscle mass associated with unloading was not prevented in the cp mice and 
that the risk for disruption of the myofibrillar structure when challenged with lengthening 
contractions was substantially elevated by unloading in cp mice suggest that inhibition of 
the calpain system is not sufficient to completely protect muscles from the structural and 
functional deficits associated with disuse.  Thus, calpain inhibition may be an important 
and effective target for preventing muscle weakness during disuse, by minimizing 
proteolytic damage to the force generating apparatus, especially in combination with 
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additional pharmacological or physical therapies aimed at preventing muscle atrophy 





Figure 2.1.  Characterization of cp mice.  Data are shown for A. confirmation by 
Western blot of over-expression of human calpastatin in soleus muscles of cp but not wt 
mice, B. Calpain activity measurements in muscle lysates from wt (open symbols) and 
cp (filled symbols) mice, C. muscle mass expressed in milligrams, D. maximum isometric 
specific force expressed in kilonewtons per square meter, and E. the deficit in isometric 
force measured one minute following two lengthening contractions expressed as the 
percent decline relative to the initial force.  In panel B, the dashed line represents the 
background level of fluorescence.  Marked activity was detected only in wt lysates 
(squares) in the presence of exogenously added calpain (5 µg/mL), and this calpain 
activity was completely inhibited in lysates from cp mice (inverted triangles).  Data are 
means ± SEM, n=3.  All values for wt lysates with exogenous calpain were significantly 
(p<0.05) above baseline as well as above the values for all other groups.  Values for cp 
lysates were not different from baseline at any point.  In panels C-E, bars represent 
means ± 1 S.E.M. for soleus and extensor digitorum longus (EDL) muscles of wt (black 
bars) and cp (gray bars) mice and the asterisk (*) indicates significant (p<0.05) 




   
 
 
Figure 2.2.  Soleus muscle mass for wt and cp mice following hindlimb 
suspension. Data are shown for masses of soleus muscles of transgenic calpastatin 
over-expressing mice (cp mice) on the right and wild type littermates (wt mice) on the left 
that were either non-suspended (Control, black bars) or exposed to 3 (white bars), 9 
(light gray bars), or 14 (dark gray bars) days of hindlimb suspension. Data are expressed 
as a percentage of the value for muscles of the controls. Bars represent means ± 1 
s.e.m. The asterisks (*) indicate significant (p<0.05) differences from the respective 




A.   
Figure 2.3 A. Representative cross sections for soleus muscles of control non-
suspended wt and cp mice.  Sections were assayed for myosin ATPase activity such 




Figure 2.3 B and C.  Individual fiber cross-sectional areas (CSAs) for soleus 
muscles following hindlimb suspension. Data are shown for the average fibers CSAs 
expressed in µm2 for B. type 1 fibers and C. type 2 fibers in soleus muscles of wild type 
(wt Mice, black bars) and calpastatin over-expressing mice (cp Mice, gray bars) that 
were either non-suspended (CT) or were exposed to 3 (3D), 9 (9D), or 14 (14D) days of 
hindlimb suspension. Bars represent means ± 1 s.e.m. The asterisk (*) indicate 








Figure 2.4.  Soleus muscle maximum isometric forces for wt and cp mice following 
hindlimb suspension. Data are shown for maximum isometric tetanic forces (Po) of 
soleus muscles of transgenic calpastatin over-expressing mice (cp mice) on the right 
and wild type littermates (wt mice) on the left that were either non-suspended (Control, 
black bars) or exposed to 3 (white bars), 9 (light gray bars), or 14 (dark gray bars) days 
of hindlimb suspension. Data are expressed as a percentage of the value for muscles of 
the controls. Bars represent means ± 1 s.e.m. The asterisks (*) indicate significant 
(p<0.05) differences from the respective values for control mice. Double asterisks (**) 






Figure 2.5.  Soleus muscle maximum isometric specific forces for wt and cp mice 
following hind limb suspension.  Data are shown for maximum isometric specific force 
(specific Po) of soleus muscles of transgenic calpastatin over-expressing mice (cp mice) 
on the right and wild type littermates (wt mice) on the left that were either non-
suspended (Control, black bars) or exposed to 3 (white bars), 9 (light gray bars), or 14 
(dark gray bars) days of hindlimb suspension. Data are expressed as a percentage of 
the value for muscles of the controls. Bars represent means ± 1 s.e.m. The asterisks (*) 
indicate significant (p<0.05) differences from the respective values for control mice. 
Double asterisks (**) indicate significant (p<0.05) differences from the 3 Day value for 
mice of the same genotype and the dagger (†) indicates a significant (p<0.05) difference 







Figure 2.6.  Sarcomere structure for soleus muscles of non-suspended wt and cp 
mice and mice exposed to 14 days of hindlimb suspension. Representative electron 
micrographs (EM) from soleus muscles of wt (A., B.) and cp (C., D.) mice that were 
either not suspended (A., C.) or exposed to 14 days of hindlimb suspension (B., D.). 


































Figure 2.7.  Thick filament lengths for soleus muscles of non-suspended wt and 
cp mice and mice exposed to 14 days of hindlimb suspension.  Thick filament 
lengths measured from muscle EMs are shown in a box plot representation. The line 
within the boxes indicates the median, while the top and bottom edges of the box 
indicate 75th and 25th percentiles, respectively. The brackets above and below the 
boxes indicate 90th and 10th percentiles, respectively and the additional symbols are 
values that fall outside the 10th to 90th %ile range. Neither means nor medians were 
different among the groups, but note increased variability in thick filament lengths for 





































































Figure 2.8.  Changes in passive resistance to stretch for soleus muscles of wt and 
cp mice following hindlimb suspension. Data are shown for the peak force during a 
passive stretch for soleus muscles of transgenic calpastatin over-expressing mice (cp 
mice) on the right and wild type littermates (wt mice) on the left that were either non-
suspended (Control, black bars) or exposed to 14 days of HS (gray bars). Data are 
expressed as a percentage of the value for muscles of the control mice. Bars represent 






Figure 2.9.  Force deficits following lengthening contractions of soleus muscles of 
wt and cp mice following hindlimb suspension. Data are shown for the deficit in 
isometric force induced following two lengthening contractions of maximally activated 
soleus muscles of transgenic calpastatin over-expressing mice (cp mice) on the right 
and wild type littermates (wt mice) on the left that were either non-suspended (Control, 
black bars) or exposed to 3 (white bars), 9 (light gray bars), or 14 (dark gray bars) days 
of hindlimb suspension. Data are expressed as the difference between the initial 
isometric force and the force immediately following the stretches expressed as a 
percentage of the initial force for each group. Bars represent means ± 1 s.e.m. The 
asterisk (*) indicates a significant (p<0.05) differences from the value for control mice 
and double asterisks (**) indicate a significant (p<0.05) difference from the 3 Day value 




Figure 2.10. Masses, maximum isometric forces, and maximum specific forces for 
EDL muscle of wt and cp mice following HS.  Data are shown for A. muscle mass, B. 
maximum isometric tetanic force (Po), and C. specific Po for EDL muscles of transgenic 
calpastatin over-expressing mice (cp mice) on the right and wild type littermates (wt 
mice) on the left that were either not exposed to hindlimb suspension (control, black 
bars) or were exposed to 3 (white bars), 9 (light gray bars), or 14 (dark gray bars) days 
of hindlimb suspension.  Data are expressed as a percentage of the value for muscles of 
the non-suspended controls.  Bars represent means + 1 s.e.m. The asterisks (*) indicate 
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TREATMENT WITH DEACETYLASE INHIBITORS DURING HINDLIMB SUSPENSION 




Deacetylase inhibitors have been reported to increase myotube size in culture 
and to induce muscle fiber hypertrophy and improvements in force generation in 
dystrophin-deficient mice.  Our objective was to investigate whether treatment with the 
deacetylase inhibitor trichostatin A (TSA) provides protection from the loss of muscle 
mass and function in healthy wild type mice subjected to hindlimb suspension (HS).  
Mice were exposed to 14 or 21 days of HS with daily administration of either TSA or a 
saline vehicle to test the hypothesis that, compared with the unloaded muscles in vehicle 
treated mice, muscles in the mice treated with TSA would show greater muscle masses, 
higher maximum isometric forces, higher specific forces normalized for cross-sectional 
area (CSA), larger individual fiber CSAs, and lower susceptibility to contraction-induced 
injury.  Following 14 or 21 days of HS, soleus muscles lost slightly less mass in TSA 
(30%) compared with vehicle (40%) treated mice, but the loss of force generating 
capacity induced by HS was not similarly prevented by TSA treatment.  In fact, specific 
force (kN/m2) showed a tendency for a continued downward trend throughout the period 
of HS for muscles of TSA treated mice.  Susceptibility to injury, as assessed by the 
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deficit in isometric force production following two lengthening contractions, was not 
different between muscles of TSA and vehicle treated mice for either non-suspended 
controls or following 14 or 21 days of HS.  Despite similar masses of soleus muscles 
from TSA and vehicle treated mice exposed to 21 days of HS, individual fiber CSAs 
were 30-40% larger and the number of fibers appearing in muscle cross sections was 
~30% smaller in the TSA treated mice.  These findings suggest an as yet unappreciated 
impact of TSA treatment on muscle architecture, which warrants future investigation.  
Based on only slight amelioration of the loss of muscle mass induced by HS provided by 
treatment with TSA that was more than compensated for by negative effects on force 
generating capacity, we conclude that the pharmacological use of deacetylase inhibitors 
to prevent muscle atrophy and maintain muscle function under circumstances of muscle 
disuse is not supported.  
 
Introduction  
Muscle atrophy and weakness are prominent features of diseases including 
cancer (Russell et al. 2009), muscular dystrophy (Spencer & Mellgren 2002), sepsis 
(Williams et al. 1999), and diabetes (Price & Mitch 1998), as well as during bed rest 
(Widrick et al. 1997) and the muscle unloading during space exploration (Gardetto et al. 
1989; Widrick et al. 1999).  Multiple studies utilizing drugs, genetic modifications, and 
exercise as therapeutic interventions have been undertaken to counteract the atrophy 
and weakness that unloading induces in skeletal muscle (Criswell et al. 1998; McMahon 
et al. 2003; Haddad et al. 2006; Arbogast et al. 2007; Trappe et al. 2009).  While most 
investigations have targeted systems that mediate protein degradation within skeletal 
muscles during disuse, a few studies have provided insight into attenuation of skeletal 
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muscle atrophy by modulation of positive or negative regulators of muscle growth.   
One positive regulator of muscle growth, IGF-I, has been shown to act at least in 
part through the inhibition of protein degradation by suppressing the expression of 
muscle specific ubiquitin ligases (Sacheck et al. 2004), but over-expression of IGF-I in a 
transgenic mouse model did not prevent muscle atrophy induced by HS (Criswell et al. 
1998).  Other investigators have examined the effectiveness of the inhibition of 
myostatin to ameliorate disuse atrophy of skeletal muscle.  Myostatin (GDF-8) is a 
member of the transforming growth factor-beta (TGF-) family of cytokines and functions 
as a negative regulator of skeletal muscle mass (McPherron et al. 1997).  Inactivation of 
the myostatin gene as well as postnatal inhibition of myostatin both result in significant 
increases in skeletal muscle mass (Zhu et al. 2000; Grobet et al. 2003; Whittemore et al. 
2003).  Moreover, myostatin-deficient mice demonstrated resistance to muscle atrophy 
induced by glucocorticoid treatment (Gilson et al. 2007), and finally, myostatin 
expression has been reported to increase following HS (Carlson et al. 1999; Lalani et al. 
2000).  Thus, while the potential of the inhibition of myostatin as a countermeasure for 
disuse atrophy appears a promising hypothesis, myostatin-deficient mice actually lost 
more muscle mass than wild type controls following HS (McMahon et al. 2003).   
Recently, treatment with deacetylase inhibitors has been explored as an 
approach to ameliorating muscle atrophy.  Protein acetylation positively influences cell 
proliferation and differentiation, and studies of C2C12 skeletal muscle cell lines and 
primary human myoblast cultures showed that treatment with deacetylase inhibitors, 
including trichostatin A (TSA), valproic acid, and phenylbutyrate, resulted in the 
formation of larger myotubes compared with myotubes formed in cultures in the absence 
of the drugs (Iezzi et al. 2002; Iezzi et al. 2004).  The effect of deacetylase inhibitors on 
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muscle cell size in vitro prompted an investigation of the efficacy of this pharmacological 
intervention to improve muscle fiber size and skeletal muscle function in dystrophic 
muscles (Minetti et al. 2006).  Treatment of mdx mice, a model of Duchenne muscular 
dystrophy, with TSA improved exercise performance, increased muscle force 
generation, and decreased susceptibility to contraction-induced injury to levels 
comparable to those of wild type mice.  An astonishing increase in individual muscle 
fiber cross-sectional areas (CSA) in mdx mice in response to TSA treatment of nearly 
two-fold relative to those in either untreated mdx mice or in wild type control mice was 
also reported in the Minetti et al. study, as were beneficial effects in mice deficient in 
alpha-sarcoglycan, a model of limb girdle muscular dystrophy type 2D (Minetti et al. 
2006).   
Although deacetylase inhibitors have been shown to induce increases in muscle 
cell size in vitro and in dystrophic mice, the ability of promoting protein acetylation as a 
means to alleviate disuse muscle atrophy in healthy mice has not been explored.  
Inasmuch as muscle regeneration has been reported to be impaired during HS (Darr & 
Schultz 1989; Mozdziak et al. 1998; Mitchell & Pavlath 2004; Fujino et al. 2005), the 
possibility that treatment with deacetylase inhibitors may counteract atrophy through the 
promotion of regenerative processes does not seem an unreasonable hypothesis.  Thus, 
the objective of the present study was to investigate the effects on wild type mice of 
treatment with the deacetylase inhibitor TSA during HS on the severity of skeletal 
muscle atrophy and loss of force generating capacity.  Mice were exposed to 14 or 21 
days of HS with daily administration of either TSA or saline vehicle to test the hypothesis 
that, compared with the unloaded muscles in vehicle treated mice, muscles in the mice 
treated with TSA would show greater muscle masses, higher maximum isometric forces, 
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larger individual fiber cross-sectional areas, and lower susceptibility to contraction-
induced injury.  
 
Methods 
All experiments were performed on 4-month-old specific pathogen free (SPF) 
male C57BL/6 mice purchased from the Jackson Laboratories (Bar Harbor, ME).  All 
procedures were approved by the University of Michigan Committee for the Use and 
Care of Animals.  A total of 36 mice were randomly assigned to one of six groups.  The 
first two groups of mice were treated with TSA and exposed to HS for either 14 (TSA-
14D) or 21 (TSA-21D) days.  Another two groups of mice were injected with vehicle and 
exposed to HS for either 14 (CON-14D) or 21 (CON-21D) days.  A fifth group of mice 
was treated with TSA for 21 days but not exposed to HS (TSA-NS).  Finally, the last 
group of mice served as undisturbed controls and were not treated with TSA or exposed 
to HS (CON-NS).  During all post-HS experimental procedures, the mice were 
anesthetized with intraperitoneal injections of 2% Avertin™ at a dose of 400 mg/kg 
tribromoethanol, with supplemental doses provided to maintain an adequate level of 
anesthesia to prevent response to tactile stimuli.   
 
Injections of TSA   
For all treated mice, TSA was administered daily by intraperitoneal injection.  The 
dose of TSA used was 0.6 mg per kg diluted in saline consistent with the dose used 
previously in mice (Minetti et al., 2006).  Untreated mice also received daily injections of 





HS is a widely used method for unloading rodent hind limbs.  Our method of HS 
was modified from that originally described by Morey (Morey 1979).  Briefly, surgical 
tape (3M, Two Harbors, MN) was used to wrap the tail of each animal against a rigid 
metal wire piece with a manually bent upper hook connected to a rotating pulley.  The 
tape was lightly soaked with liquid suture VetBond (3M, Two Harbor, MN) to create an 
instant cast.  Care was taken to prevent any VetBond from dripping onto the animal’s 
tail.  During the casting process, mice were briefly restrained in a small terrycloth wrap 
with the tail exposed.  Since the entire process of preparing the tail was completed within 
two minutes, no anesthetic was required during the procedure.  After the tape and metal 
piece were attached, mice were released into a cage until the glue was dry. Once the 
tape hardened, the hind legs of the mice were lifted slightly off the floor of the cage by 
connecting the pulley to a metal rod inside the suspension cage.  The rotating pulley 
system enabled mice to move from one end of the cage to the other with a full 360° 
range of motion and obtain food and water freely.  Mice were observed daily for changes 
in appearance and activity.  
 
In Vitro Muscle Contractile Properties 
Based on widespread reports that the soleus muscles are among the most 
sensitive to the atrophy associated with HS, and supported by our own observations in 
our previous study (Chapter 2) that showed no atrophy of mouse EDL muscles after 14 
days of HS, we chose to focus our analyses in this study on soleus muscles.  At the end 
of all treatment periods, soleus muscles in one limb were isolated under deep 
anesthesia.  5-0 silk suture ties were secured around the distal and proximal tendons, 
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and the muscles were carefully removed and placed in a horizontal bath containing 
buffered mammalian Ringer solution (composition in mM: 137 NaCl, 24 NaHCO3, 11 
glucose, 5 KCl, 2 CaCl2, 1 MgSO4, 1 NaH2PO4, and
 0.025 turbocurarine chloride) 
maintained at 25 °C and bubbled with 95% O2 / 5% CO2 to stabilize pH at 7.4.  One 
tendon of the muscle was tied securely to a force transducer (model BG-50, Kulite 
Semiconductor Products, Leonia, NJ) and the other tendon to the lever arm of a 
servomotor (model 305B, Aurora Scientific, Richmond Hill, ON, Canada).  The 
contralateral muscle was removed and prepared for future analyses.  After removal of 
the muscles, animals were euthanized with an overdose of anesthetic and administration 
of a bilateral pneumothorax. 
For measurement of isometric contractile properties, muscles were stimulated 
between two stainless steel plate electrodes.  The voltage of single 0.2-ms square 
stimulation pulses and, subsequently, muscle length (Lo) were adjusted to obtain 
maximal twitch force.  Muscle length was measured with calipers.  With the muscle held 
at Lo, the force developed during 900-ms trains of stimulation pulses
 was recorded, and 
stimulation frequency was increased until the maximum isometric tetanic force (Po) was 
achieved.  A stimulus frequency of 120 Hz typically elicited Po for all muscles.
  For each 
muscle, optimum fiber length (Lf) was calculated by
 multiplying Lo by previously 
determined Lf/Lo ratio for soleus muscles of 0.71 (Brooks & Faulkner 1988). 
Following assessment of isometric contractile properties, maximally activated 
muscles were exposed to two stretches of 30% strain relative to Lf at a velocity of
 2 Lf/s 
initiated from the plateau of an isometric contraction.  The stimulation frequency that 
elicited Po was used during the lengthening contractions.  Muscles
 were held isometric 
for 300 ms to allow near maximal activation, and stimulation was terminated at the end of 
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the lengthening ramp.  One minute of rest was allowed before the second lengthening 
contraction was initiated.  Po was measured once again 1 minute after the two 
lengthening contractions.  The force deficit induced by the lengthening contractions was 
calculated as the difference between the isometric forces measured before and after the 
stretches, expressed as a percentage of the force before the stretch.   
After the force measurements, muscles were removed from the bath, the tendons 
were trimmed, and the muscle was blotted and weighed.  Muscles were quick frozen in 
isopentane cooled with liquid nitrogen and stored at -80 °C for subsequent histological 
analyses.  Total muscle fiber cross-sectional area (CSA) was calculated by dividing the 
muscle mass by the product of Lf and the density of
 mammalian skeletal muscle, 1.06 
g/cm3.  Specific Po (in kN/m
2) was calculated by dividing Po by total fiber CSA for each 
muscle. 
 
Myosin ATPase Activity  
Frozen cross sections of 10 µm thickness were cut from the widest portion of the 
belly of each muscle.  Cryosections were placed on microscope slides and incubated at 
varying pH conditions to measure myofibrillar ATPase activity, as previously described 
(Brooke 1970).  Muscle fibers were classified as type 1 or type 2 on the basis of 
myofibrillar ATPase activity.  Stained sections were visualized on a microscope (Leitz 
Laborlux, Leica; Wetzlar, Germany) and captured with a video camera (Diagnostic 
Instruments; Sterling Heights, MI) and the image analyzing software ImageJ was used to 
calculate individual fiber areas.  For each muscle, individual fiber CSAs were evaluated 
from two entire cross sections and separated by fiber type.  Total counts of type 1 and 
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All data are presented as means ± 1 S.E.M. unless indicated otherwise.  The 
effects of treatment (CON, TSA) and duration of HS (NS, 14D, or 21D) on muscle mass, 
Po, specific Po, force deficits following lengthening contractions, single fiber CSAs, and 
fiber counts were determined by two factor analysis of variance (ANOVA) with a level of 
significance set a priori at P < 0.05.  Individual differences were determined by 




Effect of TSA on wild-type mice 
Body masses were not different between CON-NS and TSA-NS mice, but there 
was a small 14% decrease in soleus muscle mass following 21 days of TSA injections 
(Fig.3.1A).  Despite the slightly smaller mass of the muscles of TSA-NS compared with 
CON-NS mice, the values of Po for TSA-NS and CON-NS were not significantly different 
(Fig. 3.1B).  Furthermore, when Po was normalized by total muscle fiber CSA, specific Po 
values were also not different between the two groups of mice (Fig. 3.1C).  Finally, 
similar deficits in isometric force were observed for muscles of TSA-NS and CON-NS 
mice following the two lengthening contractions (Fig. 3.1D).  Collectively, these findings 
suggest that TSA treatment alone had minimal effects on the structure and function of 
soleus muscles in healthy control mice.  Based on these findings that 21 days of TSA 
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treatment had only a small impact on the muscles in non-suspended animals, we 
reasoned that the additional animal use required to include a control group of mice 
treated with TSA for 14 days but not exposed to HS was not justified.   
 
Response to Hindlimb Suspension 
Body Mass.  All mice used in this study were weighed prior to HS and at the point 
when they were sacrificed.  Most mice lost a small amount of weight during the period of 
HS, with no differences between TSA treated and vehicle treated mice.  Moreover, the 
weight loss was not progressive, that is, mice suspended for 21 days did not show 
greater weight loss than those suspended for 14 days.  Overall, for the 24 mice that 
experienced any period of HS, the average change in weight was a loss of 8% ± 1%. 
Soleus Muscle Mass.  Compared with soleus muscles of CON-NS mice, muscles 
of CON-14D mice showed a loss of mass of ~40% with no further decrease observed for 
muscles of CON-21D mice (Fig. 3.2).  Similarly, compared with soleus muscles of TSA-
NS, muscles of TSA-14D and TSA-21D also showed substantial loss of mass, with no 
difference between the 14 day and 21 day time points (Fig. 3.2).  Despite the significant 
decrease in mass following HS observed for soleus muscles of TSA treated mice, the 
decrease for the TSA treated mice was only 30% compared with the 40% decrease 
observed for vehicle treated mice, such that the relative masses of muscles of TSA 
treated mice were significantly greater than those of muscles of vehicle treated mice 
after both 14 and 21 days of HS (Fig. 3.2).   
 Contractile Properties.  Coincident with the losses of mass were decreasing 
values of Po.  Compared with the Po for CON-NS mice, Po was 47% lower for muscles of 
CON-14D mice and 53% lower for muscles of CON-21D mice (Fig. 3.3).  This greater 
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loss of force than mass during HS for the vehicle treated mice resulted in 21% and 30% 
lower values of specific Po for muscles of CON-14D and CON-21D, respectively, 
compared with the muscles of CON-NS mice (Fig. 3.4).  Despite the moderate 
attenuation of the loss of muscle mass observed for TSA treated mice, force values were 
not similarly spared.  Po for muscles of TSA-21D mice was 50% lower than the value for 
TSA-NS mice (Fig. 3.3), a decrease of similar magnitude for that observed in vehicle 
treated mice.  Again, a greater loss of force than mass during HS of TSA treated mice 
indicates that muscles in the treated mice were weaker than those in non-suspended 
mice.  Significantly lower values for specific Po were observed for muscles of both TSA-
14D (24%) and TSA-21D (40%) mice compared with the values for TSA-NS mice (Fig. 
3.4).  Furthermore, the specific Po of muscles of TSA treated mice decreased from 185 + 
8 kN/m2 for the TSA-14D group to 146 + 9 kN/m2 for the TSA-21D group, although the 
decrease did not reach statistical significance (p = 0.1).   
Susceptibility to Contraction Induced Injury. The two 30% lengthening 
contractions of maximally activated soleus muscles caused significant deficits in the 
isometric force of soleus muscles of TSA treated and vehicle treated mice that were not 
different between the groups at any time point studied (Fig. 3.5).  Despite the lack of 
difference between muscles of TSA and CON mice at any time point, force deficit was 
70% greater for muscles of CON-14D compared with CON-NS mice, whereas force 
deficit did not increase with HS for muscles of TSA treated mice.    
 Muscle Fiber Sizes.  Comparisons of the single fiber CSAs in soleus muscles 
exposed to 21 days of HS showed substantially larger fibers in TSA treated compared 
with vehicle treated mice.  Type 1 fibers in muscles of TSA-21D mice were 43% larger 
than the type 1 fibers in the muscles of CON-21D mice (Fig. 3.6A).  Similarly, type 2 
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fibers were larger for muscles of TSA-21D compared with CON-21D mice, although the 
magnitude of the difference, 32%, was slightly less than was seen for type 1 fibers.  The 
30% to 40% larger fibers in the TSA-21D muscles compared with the CON-21D muscles 
far exceeded the ~10% attenuation in the loss of muscle mass observed during HS with 
TSA treatment (Fig. 3.2).  Moreover, the absolute masses of the soleus muscles of TSA-
21D (6.5 ± 0.2 mg) and CON-21D (6.4 ± 0.2 mg) mice were not different.  In an attempt 
to reconcile the increase in average single fiber CSAs with no difference in muscle 
mass, we generated frequency histograms from the fiber CSA data (Fig. 3.6B).  
Consistent with larger mean fibers CSAs for both type 1 and type 2 fibers of the TSA 
treated mice, the frequency histograms showed clear shifts to the right for both fiber 
types, with considerable numbers of very large fibers present in the muscles of the TSA 
treated mice.  For muscles of CON-21D mice, fewer than 10% of the fibers had CSAs of 
2500 µm2 or greater, whereas nearly 40% of the fibers in the muscles of the TSA-21D 
mice exceeded 2500 µm2.  Furthermore, in muscles of TSA-21D mice, fewer than 20% 
of the fibers were smaller than 1000 µm2 compared with twice as many fibers in that size 
range in the muscles of the CON-21D mice (Fig. 3.6B).   
 Muscle Fiber Numbers.  The similarity in muscle masses for TSA-21D and CON-
21D mice, coupled with the substantially larger individual fiber CSAs in the muscles of 
TSA-21D indicates that those muscles may have fewer fibers.  Total fiber counts from 
muscle cross sections showed ~30% fewer fibers in the muscles of TSA-21D compared 
with CON-21D mice (Fig. 3.7).    
 
Discussion 
Deacetylase inhibitors have been reported to increase myotube size in culture 
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(Iezzi et al. 2004) and to induce muscle fiber hypertrophy and improvements in force 
generation in dystrophin-deficient mice (Minetti et al. 2006).  Our objective was to 
investigate whether treatment with the deacetylase inhibitor trichostatin A (TSA) 
provided protection from the loss of muscle mass and function in healthy wild type mice 
subjected to HS.  Consistent with our hypothesis, muscles in mice treated with TSA lost 
slightly less mass than those of vehicle treated mice over the course of 21 days of HS, 
however, contrary to our hypothesis, the loss of force as well as specific force was not 
different for TSA and vehicle treated mice.  In fact, there was a trend for greater loss of 
specific force for the TSA treated mice.  Thus, any beneficial effect provided by TSA 
treatment to maintain muscle mass was overcome by the weakness of the remaining 
muscle.  These findings are contrary to reports that 12 weeks of TSA treatment restored 
specific force values for muscles of mdx mice to wild type values (Minetti et al. 2006).  
Whether the relatively short duration of treatment incorporated in the present study 
explains our contrary findings is unknown, but the continued downward trend in specific 
force during HS for the muscles of our TSA treated mice argues against that possibility.   
 The larger CSAs of fibers in the TSA-21D compared with CON-21D groups are 
consistent with increased fiber sizes for muscles of mdx mice, in which after 45 days of 
TSA treatment the average single fiber CSA was 2X greater than the CSAs of either 
untreated mdx mice or wild type control mice (Minetti et al. 2006).  The increase in fiber 
sizes induced by TSA treatment in mdx mice was accompanied by increased expression 
of the TGF-β family member follistatin (Minetti et al. 2006). Increased follistatin levels 
have also been reported in muscles of TSA treated wild type mice in which muscle fiber 
degeneration and regeneration was induced by cardiotoxin injection (Iezzi et al. 2004). In 
addition, muscle fibers harvested from TSA-treated mdx mice gave rise to satellite cells 
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that showed increased follistatin expression and formed myotubes of larger diameter 
than those formed from cells harvested from tissues of untreated mice (Minetti et al. 
2006), and the up-regulation of follistatin in vivo observed following treatment with TSA 
correlated with increased expression of markers of satellite cell activation and improved 
regeneration of injured muscles in wild type mice (Iezzi et al. 2004). The in vivo findings 
are consistent with previous work showing that TSA treatment of C2C12 myoblasts 
increased follistatin expression and preventing follistatin transcription rendered 
myoblasts insensitive to TSA.  Furthermore, treatment of C2C12 cells with follistatin 
inhibitors greatly reduced TSA-mediated myoblast fusion (Iezzi et al. 2004).  Based on 
the combination of the in vitro and in vivo experiments described above, a reasonable 
hypothesis for the mechanism underlying the action of TSA appears to be that 
deacetylase inhibitors activate follistatin expression in injured muscles promoting 
enhanced activation, proliferation and fusion of satellite cells into hypernucleated 
myotubes and subsequent fusion of the newly formed myotubes with mature myofibers.  
To propose such a mechanism in our unloaded muscles requires one to accept that 
muscle fibers can simultaneously atrophy and “hypertrophy,” i.e. newly formed myotubes 
are capable of fusing with atrophying fibers in unloaded muscles.   
If individual fibers in our TSA treated animals were undergoing “hypertrophy,” 
additional changes in the architecture of the muscle must be proposed to account for the 
aggregate of our morphological data, showing that following HS there were (1) no 
differences in muscle mass or length between TSA treated and vehicle treated mice, (2) 
significantly greater individual fiber CSAs in TSA treated mice, and (3) significantly fewer 
fibers appearing in muscle cross sections of TSA treated mice.  The similar muscles 
masses for TSA and vehicle treated mice coupled with the 30-40% larger fiber CSAs in 
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the muscles of the TSA treated compared with vehicle treated mice suggests that the 
muscles in the TSA treated mice may have been losing muscle fibers during the 21 days 
of HS.  Our expectation is that fiber loss would occur as severely atrophic fibers 
ultimately disappear, yet our fiber size data shows no indication of the presence of 
severely atrophic fibers in the muscles of the TSA treated mice, although such a 
population of fibers may be observed at earlier time points.  An alternate explanation is 
that the substantially larger fibers in the muscles of the TSA treated mice caused an 
increased angle of pennation in the muscle resulting in a decreased number of fibers in 
a cross section (Maxwell et al. 1974).  Our findings are consistent with this scenario in 
principle, but the dramatic increase in pennation angle required to account for the 30% 
fewer fibers per cross-section for muscles of TSA-21D compared with CON-21D mice is 
unlikely.  Such a change in architecture also necessitates that the muscles of the TSA-
21D mice have shorter muscle fibers than muscles of CON-21D mice.  The muscles of 
both TSA treated and vehicle treated mice showed decreases in muscle length with HS 
(data not shown), but the muscle lengths were not different between the TSA and 
vehicle treated groups after either 14 or 21 days of HS.  More detailed analyses of the 
changes in muscle architecture during HS with TSA treatment is required to determine 
whether the muscles of TSA treated mice atrophy through fiber loss or decreases in fiber 
length.  The possibility that individual fibers simultaneously hypertrophy though 
deacetylase inhibitor mediated activation of satellite cells is an intriguing and potentially 
highly significant finding and warrants future investigation.   
To assess any effects of treatment with deacetylase inhibitors on susceptibility to 
contraction-induced injury, we subjected all muscles to an injurious protocol of 
lengthening contractions.  Whereas 14 days of HS increased susceptibility to injury of 
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muscles in vehicle treated mice with no further increase observed following 21 days, 
muscles in TSA treated mice showed no increase in injury susceptibility during HS.  The 
nearly two-fold increase in force deficit following lengthening contractions observed for 
muscles of CON-14D compared with CON-NS mice is consistent with the findings of our 
previous study (Chapter 2).  The observation that neither 14 nor 21 days of HS 
increased susceptibility to contraction-induced injury in TSA treated mice could be 
explained by the presence in the TSA treated mice of newly regenerated muscle fibers 
as newly regenerated fibers have been reported to be more resistant to contraction-
induced injury (Devor & Faulkner 1999).  The presence of newly regenerated fibers in 
muscles of TSA-14D or TSA-21D mice may be consistent with the hypothesis outlined 
above for the actions of TSA treatment to stimulate the activation of satellite cells 
enhancing regeneration, although any effect on susceptibility to contraction-induced 
injury as a result of the TSA treatment was not sufficient to reduce the magnitude of the 
force deficit compared with the values recorded for muscles of vehicle treated mice.   
 In summary, the findings of the present study show that treatment with the 
deacetylase inhibitor TSA resulted in a slight amelioration of the loss of muscle mass 
induced by unloading skeletal muscle during HS.  Any effect of the deacetylase inhibitor 
to preserve muscle mass, however, was more than compensated for by negative effects 
on force generating capacity such that, following HS, muscles of TSA and vehicle 
treated mice were not different with respect to isometric force production.  Despite the 
lack of beneficial effects of TSA treatment on mass or force, single fiber CSAs were 30-
40% larger in TSA treated compared with vehicle treated mice following 21 days of HS.   
These findings suggest that TSA treatment during HS may induce the fusion of newly 
formed hypernucleated myotubes with atrophying muscle, but definitive studies are 
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required to directly test this hypothesis.  Thus, although treatment with deacetylase 
inhibitors is not effective for protecting muscles from the losses of mass and force 
generating capacity associated with disuse, TSA treatment appears to be an extremely 
powerful inducer of fiber growth. 





Figure 3.1.  Effects of 21 days of TSA treatment on soleus muscles of non-
suspended mice.  Data are shown for A. muscle mass expressed in milligrams, B. 
maximum isometric tetanic force (Po) expressed in millinewtons, C. specific Po 
expressed in kilonewtons per square meter, and D. the deficit in isometric force 
measured one minute following two lengthening contractions expressed as the percent 
decline relative to the initial force for soleus of muscles of untreated (CON, black bars) 
and TSA treated (TSA, gray bars) mice.  Bars represent means + 1 s.e.m. and the 
asterisk (*) indicates a significant (p<0.05) difference between the TSA-NS and CON-NS 





Figure 3.2.  Soleus muscle mass following 14 and 21 days of hindlimb suspension 
for TSA and vehicle treated mice.  Data are shown for mass for soleus muscles of 
vehicle treated (CON, black bars) and TSA treated (TSA, gray bars) mice that were 
either not exposed to hindlimb suspension (Non-suspended) or were exposed to either 
14 (14D HS) or 21 (21D HS) days of hindlimb suspension.  Data are expressed as a 
percentage of the value for muscles of the non-suspended controls.  Bars represent 
means + 1 s.e.m. The asterisks (*) and daggers (†) indicate significant (p<0.05) 
differences from the respective values for non-suspended mice and the brackets indicate 





Figure 3.3. Soleus muscle maximum isometric force following 14 and 21 days of 
hindlimb suspension for TSA and vehicle treated mice.  Data are shown for 
maximum isometric tetanic force (Po) for soleus muscles of vehicle treated (CON, black 
bars) and TSA treated (TSA, gray bars) mice that were either not exposed to hindlimb 
suspension (Non-suspended) or were exposed to either 14 (14D HS) or 21 (21D HS) 
days of hindlimb suspension.  Data are expressed as a percentage of the value for 
muscles of the non-suspended controls.  Bars represent means + 1 s.e.m. The asterisks 
(*) and daggers (†) indicate significant (p<0.05) differences from the respective values 





Figure 3.4. Soleus muscle maximum isometric specific force following 14 and 21 
days of hindlimb suspension for TSA and vehicle treated mice.  Data are shown for 
maximum isometric tetanic force (specific Po) for soleus muscles of vehicle treated 
(CON, black bars) and TSA treated (TSA, gray bars) mice that were either not exposed 
to hindlimb suspension (Non-suspended) or were exposed to either 14 (14D HS) or 21 
(21D HS) days of hindlimb suspension.  Data are expressed as a percentage of the 
value for muscles of the non-suspended controls.  Bars represent means + 1 s.e.m. The 
asterisks (*) and daggers (†) indicate significant (p<0.05) differences from the respective 




Figure 3.5.  Force deficits following lengthening contractions of soleus muscles 
following 14 and 21 days of hindlimb suspension for TSA and vehicle treated 
mice.  Data are shown for the deficit in isometric force induced following two lengthening 
contractions of maximally activated soleus muscles of vehicle treated (CON, black bars) 
and TSA treated (TSA, gray bars) mice that were either not exposed to hindlimb 
suspension (Non-suspended) or were exposed to either 14 (14D HS) or 21 (21D HS) 
days of hindlimb suspension.  Data are expressed as the difference between the initial 
isometric force and the force immediately following the stretches expressed as a 
percentage of the initial force for each group.  Bars represent means + 1 s.e.m. The 







Figure 3.6. Individual fiber cross-sectional areas (CSAs) for soleus muscles 
following 21 days of hindlimb suspension for TSA and vehicle treated mice.  Data 
are shown for A. the average fibers CSAs expressed in µm2 and B. frequency 
distribution of fiber CSAs in soleus muscles of vehicle treated (CON-21D, black bars) 
and TSA treated (TSA-21D, gray bars) mice that were exposed to 21 days of hindlimb 
suspension.  In panel A. Bars represent means + 1 s.e.m. The asterisks (*) indicate a 




Figure 3.7. Total number of fibers that appear in a muscle cross section for soleus 
muscles following 21 days of hindlimb suspension for TSA and vehicle treated 
mice.  Data are shown for the average number of fibers appearing in muscle cross 
sections for soleus muscles of vehicle treated (CON-21D, black bars) and TSA treated 
(TSA-21D, gray bars) mice that were exposed to 21 days of hindlimb suspension.  Bars 
represent means + 1 s.e.m. The asterisk (*) indicates a significant (p<0.05) differences 
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SUMMARY AND CONCLUSIONS 
 
Summary and Significance of Major Findings 
For decades, the adaptive changes in fiber size, muscle mass, and contractility of 
skeletal muscle resulting from unloading in both humans and animals have been well 
documented.  Yet due to the complexities and unknowns of the mechanisms by which 
unloading induces changes in skeletal muscle structure and function, no effective 
remedies have been identified.  The purpose of this thesis was to investigate the impact 
of manipulating pathways that modulate either muscle protein degradation or muscle 
growth pathways on the decrease in skeletal muscle mass and force generating capacity 
that occurs in response to disuse.  Using hindlimb suspension (HS) to unload soleus 
muscles of mice the overall hypothesis was tested that inhibition of either calpain activity 
or protein deacetylase activity would ameliorate the development of muscle atrophy and 
weakness.   
 
Chapter 2 Summary.  Previous work supporting important roles for both the 
calpain and ubiquitin-proteasome systems to mediate the muscle atrophy induced by 
unloading suggests that important functional connections exist between these two 
protein degradation pathways.  The working hypothesis tested in Chapter 2 was that 
increased calpain activity in response to unloading targets specific myofibrillar proteins 
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leading to the disruption of the underlying sarcomere structure and providing substrate 
for ubiquitination.  Thus, the specific hypothesis was that following various periods of 
HS, atrophy, weakness, susceptibility to contraction-induced injury, and sarcomere 
disruption would be less severe for muscles in which calpain activity was inhibited.  
Calpain activity was inhibited through transgenic muscle-specific over-expression of 
calpastatin.   
The most significant finding of the study was that the development of muscle 
weakness was completely prevented during HS in the calpastatin over-expressing mice.  
Consistent with the maintenance of specific force during the period of unloading, 
electron microscopy demonstrated that calpain inhibition also preserved sarcomere 
structure.  The preservation of sarcomere structure in the calpastatin over-expressing 
mice during HS was in contrast to substantial disruption of sarcomeres observed in 
muscles of wild type mice exposed to HS.  We also demonstrated that calpain inhibition 
prevented the decrease in passive tension observed in wild type mice during HS.  This 
finding in addition to reports that immobilization induced changes within sarcomeres that 
were correlated with the cleavage of titin (Udaka et al. 2008) and studies indicating that 
titin has specific binding sites for calpain cleavage (Raynaud et al. 2005) are consistent 
with the hypothesis that calpain targets titin and the inhibition of calpain may protect titin.  
The beneficial effects of calpain inhibition during unloading, to maintain 
sarcomere structure and to prevent any decrease in maximum isometric specific force, 
did not extend to a prevention of the increase in susceptibility to lengthening contraction-
induced injury induced by HS.  These data suggest that the muscle weakness and the 
increased susceptibility to contraction-induced injury induced by HS are occurring 
through distinct cellular mechanisms and the effect of HS to increase contraction-
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induced injury is not mediated by calpain-dependent proteolytic activity.  Finally, calpain 
inhibition in our transgenic model did not prevent muscle atrophy after 14 days of HS.  
This result, coupled with the findings that mice deficient in either of two muscle-specific 
ubiquitin ligases, MuRF1 or MAFbx (atrogin-1), showed decreases in muscle mass of 
30% and 20%, respectively, following 14 days of denervation (Bodine et al. 2001a), 
suggests that the inhibition or even prevention of protein degradation may be insufficient 
to protect muscle completely from a loss in mass during unloading.   
 
Chapter 2 Significance to the Field.  As stated above, the most significant finding 
of the study was the prevention of the development of muscle weakness during HS 
under circumstances when calpain proteolytic activity was inhibited. This finding is 
consistent with our hypothesis that the decreased specific force observed following 
unloading is due to the disruption of the underlying sarcomere structure by the calpain 
system. Our results provide evidence that unloading leads to sustained increases in 
calcium concentration by an unknown mechanism, which leads to activation of the 
calpains that mediate the cleavage of contractile proteins within the sarcomeres resulting 
in skeletal muscle disruption and weakness.  Previous work demonstrated that mice 
deficient in muscle-specific ubiquitin ligases displayed an attenuation of disuse muscle 
atrophy (Bodine et al. 2001b), even though ubiquitination does not appear to target 
proteins within intact sarcomeres (Solomon & Goldberg 1996; Cohen et al. 2009).  Thus, 
others have hypothesized that additional degradation pathways are necessary for the 
initial cleavage of sarcomeric proteins to provide substrates for the ubiquitin-proteasome 
system (Koohmaraie 1992; Tidball & Spencer 2002; Goll et al. 2003; Fareed et al. 2006). 
The present findings provide strong support for a critical role of the calpain system in 
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targeting the force generating infrastructure of sarcomeres during disuse.   Overall, our 
results provide evidence for a model in which muscle unloading increases in vivo calpain 
mediated cleavage sarcomere proteins, possibly titin and desmin, leading to alterations 
within the sarcomere that decrease force generating capacity. 
 
Chapter 3 Summary.  Recent investigations have used pharmacological 
interventions or genetic modifications that induce skeletal muscle growth as means of 
ameliorating muscle atrophy induced by unloading.  Most of these studies have revealed 
that while such interventions were effective in inducing hypertrophy in muscles of 
normally ambulating mice, muscle atrophy induced by unloading was not prevented 
(Criswell et al. 1998; McMahon et al. 2003).  However, one class of drugs, the 
deacetylase inhibitors, has been shown to increase myotube size in vitro (Iezzi et al. 
2004), improve regeneration of injured muscles in wild type mice in vivo (Iezzi et al. 
2004), and induce muscle fiber hypertrophy and improvements in muscle contractility in 
dystrophic mice (Minetti et al. 2006).  The deacetylase inhibitors appear to act on muscle 
through the induction of the TGF- family member follistatin (Iezzi et al. 2004), which 
serves as an endogenous inhibitor of myostatin, that promotes activation and 
proliferation of satellite cells and enhances the fusion of satellite cells into 
hypernucleated myotubes and perhaps into mature myofibers (Iezzi et al. 2004; Minetti 
et al. 2006; Gilson et al. 2009).  Neither the effects nor effectiveness of these drugs on 
skeletal muscles of healthy mice during unloading had been explored.  Inasmuch as 
muscle regeneration has been reported to be impaired during HS (Darr & Schultz 1989; 
Mozdziak et al. 1998; Mitchell & Pavlath 2004; Fujino et al. 2005), the possibility that 
treatment with a deacetylase inhibitor may counteract atrophy through the promotion of 
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regenerative processes does not seem an unreasonable hypothesis.  Thus, the work 
described in Chapter 3 tested the specific hypothesis that inhibition of deacetylases by 
treating muscles with trichostatin A (TSA) would provide protection from the loss of 
muscle mass and weakness in healthy wild type mice subjected to HS.   
We observed only a slight amelioration of the loss of muscle mass in the mice 
treated with TSA compared with vehicle treated mice during 21 days of HS, and the loss 
of force as well as specific force generating capability was not different for TSA and 
vehicle treated mice.  Despite the lack of protective effects of TSA treatment on muscle 
mass or force during 21 days of HS, histological analyses showed the presence of 
substantially larger fibers in the muscles of TSA compared with vehicle treated mice.  
The larger fibers in muscles of TSA treated animals were observed with no difference 
between the groups for absolute muscle mass or length suggesting a loss of fibers from 
the muscles of the TSA treated mice, but more definitive morphological and architecture 
studies are required to test that hypothesis definitively.  In summary, the findings of this 
study provide little support for the use of deacetylase inhibitors to alleviate the structural 
and functional deficits associated with unloading.  Moreover, until the totality of the 
effects of the TSA treatment is better understood, the use of the drug under any 
circumstances should be pursued cautiously.   
 
Chapter 3 Significance to the Field.  The findings of this study have both basic 
science significance as well as applied or clinical significance.  First, with respect to the 
application of treatment with deacetylase inhibitors to lessen the negative effects of 
muscle disuse, such as during bed rest, immobilization of a limb by casting, or during 
space flight, our findings indicate that any small benefit provided to maintain muscle 
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mass was overcome by the weakness of the remaining muscle.  Thus, the beneficial 
effects of treatment with deacetylase inhibitors reported for muscles of dystrophic mice 
do not appear to extend to the setting of protecting control muscles during disuse.  
Although treatment with TSA was ineffective for protecting muscles from weakness, after 
21 days of HS, individual fiber CSAs were 30-40% larger in muscles of TSA treated mice 
compared with those in muscles of vehicle treated mice.  These findings indicate that 
inhibition of deacetylase activity is capable of inducing fiber growth, even in atrophying 
muscle.    
Our results are also of significance for the understanding of potential biological 
effects of deacetylase inhibitors in skeletal muscle.  Our observation that muscles in TSA 
and vehicle treated mice were of similar mass following 21 days of HS but were 
composed of fibers with greatly differing CSAs indicates that the TSA treatment must be 
inducing some rather dramatic architectural changes in the muscles.  One possibility is 
that the muscles of the TSA treated mice lost fibers during the period of unloading, an 
hypothesis that is supported by the fewer fibers present in the cross sections of muscles 
of TSA compared with vehicle treated mice.  An alternative explanation for the 
observation of fewer fibers appearing in the cross sections of the TSA treated group is 
that the presence of larger fibers in these muscles resulted in an increased angle of 
pennation causing fewer fibers to span any given cross section (Maxwell et al. 1974).  
Although an increased pennation angle in the muscles of TSA treated animals 
represents a reasonable hypothesis, in principle, to account for the similarity in overall 
mass with the vehicle treated muscles, a scenario of more pennate fibers also 
necessitates shorter fibers in the muscles of the TSA treated mice.  We cannot currently 
definitively explain these findings, but neither outright fiber loss nor “atrophy” of fibers 
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through reductions in fiber length accompanied by the simultaneous “hypertrophy” of 
fiber CSA are typical responses to either muscle unloading or regeneration, and these 
phenomena warrant future investigation.  
 
Future Directions   
 Consistent with our findings in Chapter 3, the presence of extremely large fibers 
in muscles of mice treated with TSA was reported by Minetti et al. for mdx mice.  Fiber 
CSAs were a full 2x larger in muscles of mdx mice treated with TSA compared with 
either untreated mdx or wild type mice (Minetti et al. 2006).  Neither muscle masses nor 
fiber numbers were reported by Minetti and colleagues, but the fiber size data indicates 
that either muscle masses were two-fold larger or additional undetermined changes 
were being induced in those muscles as appears to be the case in our TSA treated mice 
exposed to HS.  An additional possibility to explain the entirety of the morphological data 
from our TSA treated animals is the hypothesis that, while muscle fibers were 
undergoing atrophy associated with unloading, some of the fibers were fusing together.  
Although the possibility of fusion of mature myofibers represents the most reasonable 
interpretation of the aggregate of our morphological data, there is no precedent for such 
a phenomenon.  The fusion of mature myofibers seems highly unlikely as it would 
require substantial tissue remodeling, but as such the changes should be readily 
apparent if one were to examine the development of the muscle atrophy and the fiber 
“hypertrophy” over the course of the period of HS in conjunction with TSA treatment.  
The studies described in Chapter 2 provide support for the hypothesis that in the 
early days and perhaps weeks following the unloading of muscle, disruption of 
sarcomere structure is mediated by increased calpain activity.  The hypothesis that one 
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of the early and functionally important molecular targets of the calpain system is the 
cleavage of titin is supported by our observation of the maintenance of passive tension 
and uniformity of thick filament lengths in soleus muscles of calpastatin over-expressing 
mice exposed to 14 days of HS.  Future studies should pursue this hypothesis directly 
through analyses of changes in titin levels during HS under circumstances of calpain 
inhibition.  In addition, analysis of permeabilized single fibers from soleus muscles of 
unloaded wild type and calpastatin over-expressing mice can provide a more specific 
assessment of the contributions of calpain targeting of titin protein and the subsequent 
effects on passive tension.  Moreover, the ability of the inhibition of calpain proteolytic 
activity during HS suspension to prevent a decrease in specific force generation during 
isometric contractions without providing protection from an increased susceptibility to 
contraction-induced injury as well raises important questions regarding the mechanisms 
underlying the initiation of contraction-induced injury.  Clearly, the threshold in terms of 
the level of sarcomere disruption that impairs isometric force generation is greater than 
that for tolerating lengthening contractions without damage.   
While inhibition of the calpain system was able to ameliorate the muscle 
weakness that normally develops during disuse, muscle atrophy was not prevented.  
The persistence of muscle atrophy in response to disuse in muscles in which calpain 
activity was substantially inhibited fits with the views of investigators who have 
suggested that multiple molecular systems may be mediating the increased protein 
degradation during atrophy (Jackman & Kandarian 2004; Kandarian & Jackman 2006). 
Although this multifactorial effect might be at play, a few of these protein degradation 
pathways may be able to prevent the bulk of the atrophy and weakness.  Taking into 
account the prevention of muscle weakness mediated by inhibition of the calpain system 
100 
 
in this thesis and the previous finding that knocking out the skeletal muscle specific 
ubiquitin ligases reduced muscle atrophy (Bodine et al. 2001b), future studies could 
study the effects of disuse on MuRF1(-/-) or MAFbx(-/-) mice that over-express 
calpastatin as a means of also inhibiting the proteolytic activity of the calpains.  A 
synergistic inhibition of these two major degradative pathways during disuse could be 
sufficient to prevent muscle weakness and atrophy.  However, given the working model 
that the ubiquitin-proteasome system operates “downstream” of the calpains, inhibition 
of both systems may not provide any additive effect.  Inhibition or even outright 
prevention of protein degradation may be insufficient to protect muscle completely from 
a loss in mass during unloading.  Alternatively, the effects of inhibition of the ubiquitin 
proteasome system may not be the result of directly inhibiting degradation of the 
myofilaments, but instead regulation of levels of other key signaling proteins important 
for maintaining muscle protein synthesis or muscle mass.  This possibility suggests that 
approaches targeting the enhancement of protein synthesis and muscle growth (Bodine 
et al. 2001c), rather than the inhibition of protein degradation, may be necessary to fully 
counteract the atrophy associated with disuse.      
One target with potential for enhancing muscle growth, supported by previous 
work studying deacetylase inhibitors (Iezzi et al. 2004; Minetti et al. 2006) is follistatin.  
Gilson and her colleagues (Gilson et al. 2009) recently showed that over-expression of 
follistatin increased skeletal muscle satellite cell proliferation and muscle hypertrophy 
through a mechanism that was independent of the myostatin inhibitory function of 
follistatin.  Future studies could assess the effects of follistatin over-expression during 
disuse as a way to induce hypertrophy through increased satellite cell proliferation.  
While an increase in muscle growth may be insufficient on its own to overcome the 
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strong stimulatory effects of unloading on protein degradation pathways, follistatin over-
expression could be incorporated in conjunction with other therapies that inhibit 
sarcomere disruption, such as calpastatin over-expression.   
In addition, the IGF-1/PI3K/Akt pathway stimulates muscle hypertrophy through 
both its effects to induce protein synthesis and to inhibit the FOXO family of transcription 
factors that induce the upregulation of the skeletal muscle specific ubiquitin ligases 
MuRF1 and MAFbx (reviewed in Glass, 2005).  Yet, upregulation of IGF-1 was not 
sufficient to block atrophy during unloading by HS (Criswell et al. 1998).  However, a 
more recent study showed that over-expression of IGF-1 by means of electroporation 
induced a small but significant amelioration of the loss of muscle mass and density in 
soleus muscles (Alzghoul et al. 2004). Despite these potentially promising findings 
(Alzghoul et al. 2004), the issue remains of developing an effective means of activating 
the Akt/PI3K pathway in an appropriate and muscle-specific manner.  Thus, future 
studies should find ways to activate the pathway in suspended rodents in order to 
determine the specific contributions on skeletal muscle weakness and atrophy during 
disuse. 
Another pathway that may be involved in disuse-mediated muscle atrophy is the 
Nuclear Factor (NF) B pathway.  The NFB/Rel family consists of a number of distinct 
subunits, including p50/p105, p52/p100, p65 (RelA), RelB, and c-Rel, each expressed in 
skeletal muscle (Bar-Shai et al. 2005).  NFB family members play critical roles in 
modulating the specificity of NFB function, via the formation of a range of homo and 
heterodimers (Hayden & Ghosh 2008).  While key regulatory roles for NFB have been 
described in detail in immune cells, the function(s) of NFB in muscle is poorly 
understood.  In skeletal muscle, NFB has been shown to modulate expression of a 
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number of genes associated with myogenesis (Bakkar et al. 2008; Dahlman et al. 2009),  
catabolism-related genes in muscles of adult mice (Bar-Shai et al. 2005; Peterson & 
Guttridge 2008; Van et al. 2009), and cyto-protective proteins during adaptation to 
contractile activity (Vasilaki et al. 2006).  The specificity of the responses of skeletal 
muscle cells to NFB activation is also unclear, but it is likely to be largely due to subtle 
differences in NFB activation such as B binding sequences and NFB dimer formation 
that regulate expression of specific genes (Bakkar et al. 2008).  For example, skeletal 
muscle atrophy due to unloading is associated with NFB activation, although no change 
in the nuclear content of the p65 subunit is observed indicating that disuse atrophy-
induced NFB activation does not involve the canonical activation pathway (Hunter et al. 
2002; Bar-Shai et al. 2005).  Rather, the non-canonical NFB was implicated in studies 
of knock out mice for p50 or bcl-3 (an IB family member) in which muscles were 
protected from fiber atrophy following 10 days of HS (Hunter & Kandarian 2004), 
suggesting that NFB may play a causative role in the response to disuse rather than 
being activated as a consequence of atrophy.  Although the conclusion of Hunter and 
Kandarian (2004) was that disuse atrophy requires the non-canonical NFB pathway, 
neither the upstream signals nor the downstream target genes are known.  Future 
studies using microarray analysis of the genes that are altered during HS in p50 (-/-) or 
bcl-3 (-/-) mice would be useful to identify candidate triggers and downstream targets 
mediating the muscle atrophy.  
Taking together the data from Chapters 2 and 3, we propose that the 
mechanisms underlying the muscle weakness and muscle atrophy involve distinct 
molecular pathways.  These separate pathways can be observed under conditions 
where the inhibition of calpain activity in calpastatin over-expressing mice completely 
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blocked the effects of muscle disuse that cause muscle weakness but muscle atrophy 
was not prevented.  Conversely, while the effects of TSA to ameliorate the loss of 
muscle mass during HS were not dramatic, TSA treatment did partially prevent the loss 
in muscle mass without improving muscle weakness and resulted in dramatic increases 
in fiber CSAs.  This latter effect is consistent with results observed in myostatin deficient 
mice, which have marked muscular hypertrophy, but the muscles are actually weaker in 
terms of force production per cross sectional area and more susceptible to injury 
(Mendias et al. 2006).  Therefore, since the muscles ability to produce force and its 
cross-sectional area are key determinants of the overall ability of muscle to produce 
specific force, our studies suggest that therapies for muscle dysfunction following disuse 
will likely need to target calpain mediated muscle fiber damage along with the future fully 
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